28 results on '"Dedeckova, K."'
Search Results
2. Hippocampal Sparing Radiotherapy in adults with Primary Brain Tumors: A comparative planning and dosimetric study using IMPT, IMRT and 3DCRT
- Author
-
Aka, P, Taylor, R, Hugtenburg, R, Lambert, J, Powell, J, Bevolo, T, Gao, M, Gondi, V, Hartsell, W.H, Bolsi, A, Beer, J, Belosi, M.F, Siewert, D, Lomax, A.J, Weber, D.C, Huang, Y.J, Huang, C.C, Chao, P.J, Liu, C, Shang, H, Ding, X, Wang, Y, Mammar, H, Froelich, Sébastien, Alapetite, Claire, Bolle, Stéphanie, Calugaru, Valentin, Feuvret, Loic, Helfre, Sylvie, Champion, Laurence, Goudjil, Farid, Dendal, Remi, Engelholm, S.A, Munck Af Rosenschold, P, Kristensen, I, Smulders, B, Muhic, A, Alkner, S, Jacob, E, Engelholm, S, Aljabab, S, Lui, A, Wong, T, Liao, J, Laramore, G, Parvathaneni, U, Kharouta, M, Pidikiti, R, Jesseph, F, Smith, M, Dobbins, D, Mattson, D, Choi, S, Mansur, D, Machtay, M, Bhatt, A, Lütgendorf-Caucig, C, Dunavölgyi, R, Georg, P, Perpar, A, Fussl, C, Konstantinovic, R, Ulrike, M, Piero, F, Eugen, H, Vidal, M, Gerard, A, Barnel, C, Maneval, D, Herault, J, Claren, A, Doyen, J, Dendale, R, Toutee, A, Pasquie, I, Goudjil, F, Lumbroso Lerouic, L, Levy, C, Desjardins, L, Cassoux, N, Elisei, G, Pella, A, Calvi, G, Ricotti, R, Tagaste, B, Valvo, F, Ciocca, M, Via, R, Mastella, E, Baroni, G, Saotome, N, Yonai, S, Makishima, H, Hara, Y, Inaniwa, T, Sakama, M, Kanematsu, N, Tsuji, H, Furukawa, T, Shirai, T, Sauerwein, W, Finger, P.T, Gallie, B, Gavrylyuk, Y, Thariat, J, Salleron, J, Maschi, C, Fevrier, E, Caujolle, J.P, Hofverberg, P, Angellier, G, Peyrichon, M.L, Breneman, J, Esslinger, H, Pater, L, Vatner, R, Habrand, J.L, Stefan, D, Lesueur, P, Kao, W, Véla, A, Geffrelot, J, Tessonnier, T, Balosso, J, Mahé, M.A, Lim, P.S, Rompokos, V, Chang, Y.C, Royle, G, Gaze, M, Gains, J, Vennarini, S, Francesco, F, Rombi, B, Amichetti, M, Schwarz, M, Lorentini, S, Mee, T, Burnet, N.G, Crellin, A, Kirkby, N.F, Smith, E, Kirkby, K.J, Roggio, M, Buwenge, M, Melchionda, F, Ammendolia, I, Ronchi, L, Cammelli, S, Morganti, A.G, Youn, S.H, Kim, J.Y, Park, H.J, Shin, S.H, Lee, S.H, Hong, E.K, Czerska, K, Winczura, P, Wejs-Maternik, J, Blukis, A, Antonowicz-Szydlowska, M, Rucinski, A, Olko, P, Badzio, A, Kopec, R, Franceschini, D, Cozzi, L, De Rose, F, Meattini, I, Fogliata, A, Cozzi, S, Becherini, C, Tomatis, S, Livi, L, Scorsetti, M, Garda, A, Fattahi, S, Michel, A, Mutter, R, Yan, E, Park, S, Corbin, K, Giap, H, LAM, W.W, Geng, H, Tang, K.K, Lee, T.Y, Kong, C.W, Yang, B, Chiu, T.L, Cheung, K.Y, Yu, S.K, Ma, M, Gao, X, Zhao, Z, Zhao, B, Mullikin, T, Routman, D, Yu, J, Greco, K, Fagundes, M, Shan, J, Daniels, T, Rule, W, DeWees, T, Hu, Y, Bues, M, Sio, T, Liu, W, chenbin, L, yuehu, P, yuenan, W, Bai, Y, Gao, X.S, Zhao, Z.L, Ma, M.W, Ren, X.Y, Salem, A, Woolf, D, Aznar, M, Azadeh, A, Eccles, C, Charlwood, F, Faivre-Finn, C, Teoh, S, Fiorini, F, George, B, Vallis, K, Van den Heuvel, F, Huang, E.Y, Juang, P.J, Pan, S, Hawkins, M, Clarke, M, Lowe, M, Radhakrishna, G, Schaub, S, Bowen, S, Nyflot, M, Chapman, T, Apisarnthanarax, S, Vitek, P, Kubes, J, Vondracek, V, Vinakurau, S, Zamecnik, L, Vitolo, V, Barcellini, A, Brugnatelli, S, Cobianchi, L, Vanoli, A, Fossati, P, Facoetti, A, Dionigi, P, Orecchia, R, Iannalfi, A, Vischioni, B, Ronchi, S, D’Ippolito, E, Petrucci, R, Yamaguchi, H, Honda, M, Hamada, K, Todate, Y, Seto, I, Suzuki, M, Wada, H, Murakami, M, Yu, Z, Zheng, W, Lien-Chun, L, Zhengshan, H, Qing, Z, Jiade, L, Guoliang, J, Fiore, M.R, D'Ippolito, E, Fukumitsu, N, Hayakawa, T, Yamashita, T, Mima, M, Demizu, Y, Suzuki, T, Soejima, T, Hartsell, W, Collins, S, Casablanca, V, Mihalcik, S, Brennan, E, Van Nispen, A, Corbett, A, Mohammed, N, Lee, P, van Nispen, A, Liang, Y.S, Mein, S, Kopp, B, Choi, K, Haberer, T, Debus, J, Abdollahi, A, Mairani, A, Ogino, H, Iwata, H, Hashimoto, S, Nakajima, K, Hattori, Y, Nomura, K, Shibamoto, Y, Li, P, Wu, S, Deng, L, Zhang, G, Zhang, Q, Fu, S, Yang, Z, Zhang, Y, Sasaki, R, Okimoto, T, Akasaka, H, Miyawaki, D, Yoshida, K, Wang, T, Komatsu, S, Fukumoto, T, Shuang, W, Xin, C, zhengshan, H, Shen, F, Vorobyov, N, Andreev, G, Martynova, N, Lyubinsky, A, Kubasov, A, Chen, J, Ma, N, Lu, Y, Zhao, J, Shahnazi, K, Lu, J, Jiang, G, Mao, J, Walser, M, Bojaxhiu, B, Kawashiro, S, Tran, S, Pica, A, Bachtiary, B, Weber, D, Gaito, S, Abravan, A, Richardson, J, Colaco, R, Saunders, D, Brennan, B, Petersen, I, Ahmed, S, Laack, N, Mizoe, J.E, Iizumi, T, Minohara, S, Kusano, Y, Matsuzaki, Y, Tsuchida, K, Serizawa, I, Yoshida, D, Katoh, H, Sakurai, H, Tujii, H, Kim, T.H, Park, J.W, Bo Hyun, K, Hyunjung, K, Sung Ho, M, Sang Soo, K, Sang Myung, W, Young-Hwan, K, Woo Jin, L, Dae Yong, K, Hong, Z, Wang, Z, Koroulakis, A, Molitoris, J, Kaiser, A, Hanna, N, Jiang, Y, Regine, W, DeCesaris, C.M, Choi, J.I, Carr, S.R, Burrows, W.M, Regine, W.F, Simone, C.B, Aihara, T, Hiratsuka, J, Kamitani, N, Higashino, M, Kawata, R, Kumada, H, Ono, K, Chou, Y.C, Dippolito, E, Bonora, M, Alterio, D, Gandini, S, Jereczeck, B.A, Kelly, C, Dobeson, C, Iqbal, S, Chatterjee, S, Hague, C, Li, T, Lin, A, Lukens, J, Slevin, N, Thomson, D, van Herk, M, West, C, Teo, K, Jeans, E, Manzar, G, Patel, S, Ma, D, Lester, S, Foote, R, Friborg, J, Jensen, K, Hansen, C.R, Andersen, E, Andersen, M, Eriksen, J.G, Johansen, J, Overgaard, J, Grau, C, Dědečková, K, Vítek, P, Ondrová, B, Sláviková, S, Zapletalová, S, Zapletal, R, Vondráček, V, Rotnáglová, E, Kwanghyun, J, Woojin, L, Dongryul, O, Yong Chan, A, Paudel, N, Schmidt, S, Ruckman, M, Gans, S, Stauffer, M, Helenowski, I, Patel, U, Samant, S, Gentile, M, Damico, N, Yao, M, Shuja, M, Routman, D.M, Foote, R.L, Garces, Y.I, Neben-Wittich, M.A, Patel, S.H, McGee, L.A, Harmsen, W.S, Ma, D.J, Sommat, K, Tong, A.K.T, Hu, J, Ong, A.L.K, Wang, F, Sin, S.Y, Wee, T.S, Tan, W.K, Fong, K.W, Soong, Y.L, Wallace, N, Fredericks, S, Fitzgerald, T, Vernimmen, F, Petringa, G, Cirrone, P, Agosteo, S, Attili, A, Cammarata, F.P, Cuttone, G, Conte, V, La Tessa, C, Manti, L, Rosenfeld, A, Lojacono, P.A, Hennings, F, Fattori, G, Peroni, M, Lomax, A, Hrbacek, J, Nguyen, H.G, Bach Cuadra, M, Sznitman, R, Schalenbourg, A, Pflaeger, A, Weber, A, Seidel, S, Stark, R, Heufelder, J, Mailhot Vega, R, Bradley, J, Lockney, N, Macdonald, S, Liang, X, Mazal, A, Mendenhall, N, Sher, D, Korreman, S.S, Andreasen, S, Petersen, J.B, Offersen, B.V, Gergelis, K, Jethwa, K, Whitaker, T, Shiraishi, S, Shumway, D, Press, R, Shelton, J, Zhang, C, Dang, Q, Tian, S, Shu, T, Seldon, C, Jani, A, Zhou, J, McDonald, M, Gort, E, Beukema, J.C, Spijkerman-Bergsma, M.J, Both, S, Langendijk, J.A, Matysiak, W.P, Brouwer, C.L, Baba, K, Numajiri, H, Murofushi, K, Oshiro, Y, Mizumoto, M, Onishi, K, Nonaka, T, Ishikawa, H, Okumura, T, Dominietto, M, Adam, K, Ahlhelm, F.J, Safai, S, Abdul-Jabbar, L, Song, J, Tseng, Y. D, Rockhill, J, Fink, J, Chang, L, Halasz, L. M, Guntrum, F, Steinmeier, T, Nagaraja, S, Jazmati, D, Geismar, D, Timmermann, B, Plaude, S, Lynch, C, Petras, K, Chang, J, Grimm, S, Lukas, R, Kumthekar, P, Merrell, R, Kalapurakal, J, Gross, J, Hoppe, B, Simone, C, Nichols, R.C, Pham, D, Mohindra, P, Chon, B, Morris, C, Li, Z, Flampouri, S, Powell, J.R, Murray, L, Burnet, N, Fernandez, S, Lingard, Z, McParland, L, O’Hara, D, Whitfield, G, Short, S.C, Guan, X, Gao, J, Hu, W, Yang, J, Xing, X, Hu, C, Kong, L, Zou, Z, Thomas, H, Sasidharan, B.K, Rengan, R, Zeng, J, Busold, S, Heese, J, Cerello, P, Bottura, L, Felcini, E, Ferrero, V, Monaco, V, Pennazio, F, de Rijk, G, Chang, H, KyungDon, C, Byunghun, H, Gyuseong, C, Chilukuri, S, Jalali, R, Panda, P.K, Korn, G, Larosa, G, Russo, A, Schillaci, F, Scuderi, V, Margarone, D, Fredén, E, Almhagen, E, Mejaddam, Y, Siegbahn, A, Guardiola, C, Gómez, F, Prieto-Pena, J, Fleta, C, De Marzi, L, Prezado, Y, Kabolizadeh, P, Reitemeier, P, Navin, M, Hamstra, D, Anderson, J, Stevens, C, Bartolucci, L, Adrien, C, Lejars, M, Vaillant, M, Fourquet, A, Robillard, M, Costa, E, Kirova, Y, Kolano, A.M, Degiovanni, A, Farr, J.B, Kundel, S, Pinto, M, Kurichiyanil, N, Würl, M, Englbrecht, F, Hillbrand, M, Schreiber, J, Parodi, K, Kurup, A, Magliari, A, Perez, J, Masui, S, Asano, T, Owen, H, Burt, G, Apsimon, R, Pitman, S, Popovici, M.A, Vasilache, R, Safavi-Naeini, M, Chacon, A, Howell, N, Middleton, R.J, Fraser, B, Guatelli, S, Rendina, L, Matsufuji, N, Gregoire, M.C, Sikora, K, Pettingell, J, Crocker, M, Saplaouras, A, Snijders, A, Mao, J.H, Nakamura, K, Bin, J, Gonsalves, A, Mao, H.S, Steinke, S, Roach, M, Leemans, W, Blakely, E, Takayama, K, Tan, T.S, Wee, J.T.S, Tuan, J.K.L, Wang, M.L.C, Quah, J.S.H, Tay, N.C.W, Lee, J.C.L, Lim, J.K.H, Oei, A.A, Tan, J.M, Park, S.Y, Chow, W.W.L, Omar, Y.B, Chew, P.G, Taylor, P, Lee, J, Tsurudome, T, Hirabayashi, M, Tsutsui, H, Yoshida, J, Takahashi, N, Kamiguchi, N, Hashimoto, A, Tachikawa, T, Mikami, Y, Kumata, Y, Wang, M, Chua, E.T, Wee, J, Wong, F.Y, Tuan, J, Master, Z, Wong, S, Welsh, J, Hentz, C, Pankuch, M, DeJongh, F, Xia, Y, Aitkenhead, A.H, Appleby, R, Merchant, M.J, MacKay, R.I, Young, H, Hughes, V, Alsulimane, M, Barajas, C.A, Taylor, J, Casse, G, Omar, A, Burdin, S, Boon, C, Lester, J, Thomas, A.J, Khan, A, Huthart, L, Leaver, K, Snell, J, Warlow, A, Burigo, L.N, Oborn, B, Belosi, F, Fredh, A, van de Water, S, Schneider, T, Patriarca, A, Bergs, J, Hierso, E, Hirayama, R, Martínez-Rovira, I, Seksek, O, Shirato, H, Nakamura, T, Ogino, T, Akimoto, T, Tamamura, H, Nishimoto, N, Proton-Net, G, Shimizu, S, Fabiano, S, Bangert, M, Guckenberger, M, Unkelbach, J, Mcauley, G, Teran, A, Slater, J, Wroe, A, Boon, I, Clorley, J, Owen, K, Oliver, T, Cicchetti, A, Ballarini, F, Rancati, T, Carrara, M, Zaffaroni, N, Bezawy, R. El, Carante, M, Valdagni, R, Faccini, R, Forte, G.I, Dhinsey, S, Greenshaw, T, Parsons, J, Welsch, C, Stock, M, Grevillot, L, Kragl, G, Carlino, A, Martino, G, Hug, E, Arya, H, Chirayath, V.A, Jin, M, Weiss, A.H, Glass, G.A, Chi, Y, Kaplan, L.P, Perez, R.A, Vestergaard, A, Gittings, E, Stamper, J, Beltran, C, Mark, P, Furutani, K, McAuley, G, Gordon, J, Boisseau, P, Dart, A, Nett, W, Kollipara, S, Grossmann, M, Actis, O, Diete, W, Rudolf, D, Klein, H.U, Kramert, R, Meer, D, Venkataraman, C, Waterstradt, T, Hérault, J, Bergerot, J.M, Hsi, W.C, Zhou, R, Zhang, X, Yang, F, Yinxiangzi, S, Sun, J, Li, X, Zhiling, C, Yuehu, P, Mengya, G, Haiyun, K, Qi, L, Zhentang, Z, Lin, Y.H, Tan, H.Q, Tan, L.K.R, Ang, K.W, Xiufang, L, Milkowski, K, Pang, D, Jones, M, Mizota, M, Tsunashima, Y, Himukai, T, Ogata, R, Uno, T, Ouyang, L, Jia, B, Li, D, Paul, K, Pullia, M, Savazzi, S, Lante, V, Foglio, S, Donetti, M, Falbo, L, Casalegno, L, Rousseau, M, Shinomiya, K, Yazawa, T, Iseki, Y, Kanai, Y, Hirata, Y, Powers, J, Solovev, A, Chernukha, A, Saburov, V, Shegai, P, Ivanov, S, Kaprin, A, Stolarczyk, L, Mojżeszek, N, Van Hoey, O, Farah, J, Domingo, C, Mares, V, Ploc, O, Trinkl, S, Harrison, R, Toltz, A, Nevitt, Z, Bloch, C, Taddei, P, Saini, J, Regmi, R, Yuntao, S, Jinxing, Z, Yap, J.S.L, Hentz, M, Silverman, J, Jolly, S, Boogert, S, Nevay, L, Kacperek, A, Schnuerer, R, Resta-Lopez, J, Zeng, X, Zheng, J, Li, M, Han, M, Song, Y, Holm, A, Korreman, S, Petersen, J.B.B, Bäumer, C, Fuenstes, C, Janson, M, Matic, A, Wulff, J, Psoroulas, S, Lomax, T, Arjomandy, B, Athar, B, Tesfamicael, B, Bejarano Buele, A, Deemer, J, Kozlyuk, V, VanSickle, K, Bolt, R, van Goethem, M.J, Langendijk, J, van t Veld, A, Chen, K.L, Wlodarczyk, B, Wu, H, Chen, Z, Shen, L, Fachouri, N, Placidi, L, Böhlen, T, Ieko, Y, Iwai, T, Nemoto, K, Suzuki, K, Kanai, T, Miyasaka, Y, Harada, M, Yamashita, H, Kubota, I, Kayama, T, Jensen, M.F, Bræmer-Jensen, P, Randers, P, Søndergaard, C.S, Nørrevang, O, Taasti, V.T, Kong, H, Yin, C, Gu, M, Liu, M, Shu, H, Chongxian, Y, Haiyang, Z, Juan, Z, Ming, L, Manzhou, Z., Liying, Z, Kecheng, C, Xiaolei, D, Castro, J, Freire, J, Cremades, M, Moral, L, Rico, P, Ares, C, Miralbell, R, Shi, J, Xia, J, Wang, B, Li, Q, Liu, X, Sung, C.C, Chen, W.P, Liao, T.Y, Takashina, M, Hamatani, N, Tsubouchi, T, Yagi, M, Mizoe, J, Titt, U, Mirkovic, D, Yepes, P, Wang, Q, Grosshans, D, Wieser, H.P, Mohan, R, Vadrucci, M, Xiao, G, Cai, X, Li, G, Yuan, Y, Lu, R, Sun, G, Zhang, M, Deming, L, lianhua, O, Takada, K, Tanaka, S, Matsumoto, Y, Naito, F, Kurihara, T, Nakai, K, Matsumura, A, Sakae, T, Shamurailatpam, D, P, K, Mp, N, A, M, Kg, G, T, R, C, S, J, R, Rozes, A, Dutheil, P, Batalla, A, Vela, A, Rana, S, Bennouna, J, Gutierrez, A, He, P, Shen, G, Dai, Z, Ma, Y, Chen, W, Pandey, J, Chirvase, C, Osborne, M, Ilsley, E, Di Biase, I, Kato, T, Hirose, K, Arai, K, Motoyanagi, T, Harada, T, Takeuchi, A, Kato, R, Tanaka, H, Mitsumoto, T, Takai, Y, Bolsa-Ferruz, M, Palmans, H, Chen, Y.S, Wu, S.W, Huang, H.C, Wang, H.T, Yeh, C.Y, Chen, H.H, Cook, H, Lourenço, A, Dal Bello, R, Magalhaes Martins, P, Hermann, G, Kihm, T, Seimetz, M, Brons, S, Seco, J, De Saint-Hubert, M, Swakon, J, De Freitas Nascimento, L, Tessaro, V.B, Poignant, F, Gervais, B, Beuve, M, Galassi, M.E, Harms, J, Chang, C.W, Zhang, R, Lin, Y, Langen, K, Liu, T, Lin, L, Howard, M, Denbeigh, J, Remmes, N, Debrot, E, Herman, M, Huang, Y.Y, Tsai, S.H, Fang, F.M, Mizuno, H, Sagara, T, Yamazaki, Y, Kato, M, Oyama, S, Pembroke, C, Joslin-Tan, T, Maggs, R, O’Neil, K, Barrett-Lee, P, Staffurth, J, Resch, A, Heyes, P, Georg, D, Fuchs, H, Hideyuki, M, katsuhisa, N, Wataru, Y, Samnøy, A.T, Ytre-Hauge, K.S, Povoli, M, Kok, A, Summanwar, A, Linh, T, Malinen, E, Röhrich, D, Asp, J, Santos, A, Afshar, V.S, Zhang, W.Q, Bezak, E, a, M, k, G, p, K, mp, N, t, R, c, S, j, R, Smith, B, Hammer, C, Hyer, D, DeWerd, L, Culberson, W, Brooke, M, Straticiuc, M, Craciun, L, Matei, C.E, Radu, M, Xiao, M, Paschalis, S, Joshi, P, Price, T, Mehta, M, Graça, J, Biglin, E, Aitkenhead, A, Price, G, Williams, K, Chadwick, A, Schettino, G, Robinson, A, Kirkby, K, Catanzano, D, Cessac, R, Rutherford, R, Ahmed, A, Mohammadi, A, Tashima, H, Yamaya, T, Chavez Barajas, C, Taylor, A, Vossebeld, J, Barwick, I, CHEON, W, Jo, K, Ahn, S.W, Cho, J, Han, Y, Choi, H.H.F, Cheung, C.W, Cohilis, M, Lee, J.A, Sterpin, E, Souris, K, Mundy, D, Petasecca, M, Rosenfeld, A.B, Boso, A, Di Fulvio, A, Becchetti, F.D, Torres-Isea, R.O, Febbraro, M, Gagnon-Moisan, F, Feng, Y, Fontana, M, Etxebeste, A, Dauvergne, D, Letang, J.M, Testa, E, Sarrut, D, Maxim, V, Gajewski, J, Durante, M, Garbacz, M, Krah, N, Krzempek, K, Schiavi, A, Skrzypek, A, Tommasino, F, Ruciński, A, Gillin, M, Sahoo, N, Zhu, X.R, Van Delinder, K.W, Crawford, D, Khan, R, Gräfe, J, Kakiuchi, G, Shioyama, Y, Shimokomaki, R, Huang, Z, Wang, W, Sheng, Y, Lee, M.W, Jan, M.L, Hong, J.H, Okamoto, K, Sato, H, Kalantan, S, Boston, A, Kang, Y, Shen, J, Casey, W, Vern-Gross, T, Wong, W, McGee, L, Halyard, M, Keole, S, Kelleter, L, Radogna, R, Saakyan, R, Basharina-Freshville, A, Attree, D, Volz, L, Komenda, W, Krzempek, D, Mierzwińska, G, Barbara, M, Kopeć, R, Lan, J.H, Chang, F.X, Lin, C.H, Lee, T.F, Ahn, S, Cheon, W, Lee, M, Letellier, V, Osorio, J, Dreindl, R, Livingstone, J, Gallin-Martel, M.L, Létang, J.M, Marcatili, S, Morel, C, Maggi, P, Chen, H, Yang, H, Panthi, R, Mackin, D, Peterson, S, Beddar, S, Polf, J, Masuda, T, Nishio, T, Sano, A, Tomozawa, H, Nishio, A, Tsuneda, M, Okamoto, T, Karasawa, K, Miszczynska Giza, O, Sánchez-Parcerisa, D, Herraiz, J. L, Rojo-Santiago, J, Udias, J.M, Mitrović, U, Hager, M, List, I, Fischer, C, Cecowski, M, Gajšek, R, Mizutani, S, Hotta, K, Baba, H, Tanizaki, N, Yamaguchi, T, Moon, S.Y, Rah, J.E, Yoon, M, Shin, D, Nebah, P, Dugas, J, Syh, J, Maynard, M, Marsh, N, Rosen, L, Nichiporov, D, Watts, D.A, Chen, Y, Petterson, M, Lee, W.D, Penfold, S.N, Ruebel, N, Piersimoni, P, Mille, M, Mossahebi, S, Chen-Mayer, H, Allport, P, Green, S, Shaikh, S, Walker, D, Qamhiyeh, S, Levegruen, S, Kutscher, S, Kranke, H, Olbrich, G, Stuschke, M, Baran, J, Pawlik-Niedzwiecka, M, Moskal, P, Rutherford, H, Poenisch, F, Martin, C, Wu, R, Mayo, L.L, Shah, S.J, Frank, S.J, Gunn, G.B, Sakurai, Y, Takata, T, Kondo, N, Schlegel, N, Deng, Y, Sun, W, Wu, X, Yap, J, Zhang, H, Szumlak, T, Schuy, C, Simeonov, Y, Zink, K, Graeff, C, Weber, U, Allred, B, Robertson, D, Dewees, T, Gagneur, J, Stoker, J, Stützer, K, Valentini, C, Agolli, L, Hölscher, T, Thiele, J, Dutz, A, Löck, S, Krause, M, Baumann, M, Richter, C, Takayanagi, T, Uesaka, T, Nakamura, Y, Unlu, M.B, Kuriyama, Y, Uesugi, T, Ishi, Y, Umegaki, K, Matsuura, T, Watts, D. A, Huisman, B, Valladolid Onecha, V, Fraile, L.M, Sanchez Parcerisa, D, España, S, Ze, W, Chen, H.Y, Chuang, K.S, Wilson, M, Lui, J, Noble, D, Holloway, S, Yap, J.H.H, Chew, M.M.L, Pang, P.P, Lim, C.J.C, Gan, S.A, Tan, T.W.K, Shen, Z.M, Moyers, M, Qianxia, W, Chen, H.L, Li, J, Lin, J, Zhao, L, Myers, W, Ates, O, Faught, J, Yan, Y, Faught, A, Sobczak, D, Hua, C.H, Moskvin, V, Merchant, T, Henkner, K, Ecker, S, Chaudhri, N, Ellerbrock, M, Jäkel, O, Hernandez Morales, D, Augustine, K, Johnson, J, Younkin, J, Fiorina, E, Mattei, I, Morrocchi, M, Sarti, A, Traini, G, Valle, S.M, Bert, C, Karger, C.P, Kamada, T, Scholz, M, DeLuca, P.M, De Simoni, M, Dong, Y, Embriaco, A, Fischetti, M, Mancini-Terracciano, C, Mirabelli, R, Muraro, S, Lens, E, de Blécourt, A, Schaart, D, Vos, F, van Dongen, K, Berthold, J, Khamfongkhruea, C, Petzoldt, J, Wohlfahrt, P, Pausch, G, Janssens, G, Smeets, J, Shamblin, J, Blakey, M, Moore, R, Matteo, J, Schreuder, N, Derenchuk, V, Shin, J, Jee, K.W, Clasie, B.M, Depauw, N, Batin, E, Madden, T.M, Schuemann, J, Paganetti, H, Kooy, H.M, Daniel, M, Abbassi, L, Arsène-Henry, A, Amessis, M, Maes, S, O’Ryan-Blair, A, Laval, G, Ermoian, R, Taddei, P. J, Andersson, K, Norrlid, O, Lindbäck, E, Vallhagen Dahlgren, C, Witt Nyström, P, Argota Perez, R, Sharma, M.B, Elstrøm, U.V, Bizzocchi, N, Albertini, F, Branco, D, Kry, S, Rong, J, Frank, S, Followill, D, Busch, K, Muren, L.P, Thörnqvist, S, Andersen, A.G, Pedersen, J, Dong, L, Cao, W, Bai, X, Van Lobenstein, N, Traneus, E, Anson, C, Comi, S, Marvaso, G, Russo, S, Giandini, T, Avuzzi, B, Ciardo, D, Cattani, F, Jereczek-Fossa, B, Cotterill, J, Esposito, M, Winter, A, Allinson, N, Liu, G, Yan, D, Jawad, S, Dilworth, J, Chen, P, Ackermann, B, Florijn, M, Sharfo, A.W.M, Wiggenraad, R.G.J, van Santvoort, J.P.C, Petoukhova, A.L, Hoogeman, M.S, Mast, M.E, Dirkx, M.L.P, Fujitaka, S, Fujii, Y, Nihongi, H, Nakayama, S, Ho, M.W, Artz, M, Tong, K.T.A, Hytonen, R, Koponen, T, Niemela, P, Iancu, G, Lautenschlaeger, S, Eberle, F, Horst, F, Ringbaek, T, Engenhart-Cabillic, R, Kim, M.J, Hong, C.S, Kim, Y.B, Park, S.H, Kim, J.S, Reiterer, J, Steffal, C, Gora, J, Kann, T, Schratter-Sehn, A.U, Li, H, Chen, M, wu, R, Li, Y, zhang, X, Gautam, A, poenisch, F, sahoo, N, Zhu, R, Lin, M, Chang, J.T.C, Maeda, Y, Sato, Y, Shibata, S, Bou, S, Yamamoto, K, Sasaki, M, Fuwa, N, Takamatsu, S, Kume, K, Lim, F, Faller, F, Stiller, W, Ming, X, Hui, H, Mukawa, T, Takashi, Y, Stephenson, L, Pang, E.P.P, Paz, A.E, Yoshida, Y, Righetto, R, Vecchi, C, Alparone, A, De Spirito, M, Radhakrishnan, S, Chandrashekaran, A, Nandigam, J, Sarma, Y, Rechner, L, Munck af Rosenschöld, P, Bäck, A, Johansen, T.S, Schut, D.A, Aznar, M.C, Nyman, J, Ren, X, Rosas, S, Vanderstraeten, R, Jyske, T, Jari, L, Yuenan, W, Henthorn, N, Warmenhoven, J, Merchant, M, Kirkby, N, Ranald, M, Stefanowicz, S, Zschaeck, S, Troost, E.G.C, Stubington, E, Ehrgott, M, Nohadani, O, Shentall, G, Sun, T, yin, Y, Lin, X, Yoshimura, T, Matsuo, Y, Yamazaki, R, Takao, S, Miyamoto, N, Toussaint, L, Indelicato, D.J, Lassen-Ramshad, Y, Kirby, K, Mikkelsen, R, Di Pinto, M, Høyer, M, Stokkevåg, C.H, Van Herk, M, Shortall, J, Green, A, Vasquez Osorio, E, Mackay, R, Navratil, M, Andrlik, M, Chiang, Y.Y, Yeh, Y.H, Yeh, Y.J, Chang, T.C, Eaton, B, Yang, X, Esiashvili, N, Gu, W, Ruan, D, O’Connor, D, Zou, W, Tsai, M.Y, Jia, X, Sheng, K, Hyde, C, Chen, P.Y, Deraniyagala, R, Petoukhova, A, Klaassen, L, Habraken, S, Jacobs, J, Sattler, M, Verhoeven, K, Klaver, Y, Widesott, L, Fracchiolla, F, Algranati, C, Scifoni, E, Scartoni, D, Farace, P, Kröniger, K, Bauer, J, Nilsson, R, Chen, X, Liu, R, Sun, B, Mutic, S, Zhang, T, Zhao, T, Kajdrowicz, T, Wochnik, A, Swakoń, J, Małecki, K, Michalec, B, Moffitt, G, Wootton, L, Hardemark, B, Sandison, G, Emery, R, Stewart, R, Reidel, C.A, Finck, C, Deisher, A, Mahajan, A, Michael, H, Ahn, S.H, Kwang Hyeon, K, Chankyu, K, Youngmoon, G, Shinhaeng, C, Se Byeong, L, Young Kyung, L, Haksoo, K, Dongho, S, Jong Hwi, J, Ali, Y, Monini, C, Maigne, L, Alshaikhi, J, D’Souza, D, Amos, R. A, Baumann, K.S, Gomà, C, Flatten, V, Lautenschläger, S, Abdel-Rehim, A, Wan Chan Tseung, H.S, Ma, J, Kamal Syed, H, Boscolo, D, Krämer, M, Fuss, M, Braunroth, T, Rabus, H, Baek, W.Y, Brown, H, Alshammari, H, Brownstein, J, Giantsoudi, D, Wang, C.C, Grassberger, C, Chen, C, Chan, M.F, Mah, D, Hojo, Y, Xu, C, Elia, A, Fung, A, Nguyen, B.N, Oyervides, M, Koska, B, Kamal Sayed, H, Kim, C, Kim, Y.J, Lee, S.B, Goh, Y, Cho, S, Jeong, J.H, Kim, H, Lim, Y.K, Koh, W.Y.C, Lew, W.S, Lee, C.L.J, Kollitz, E, Han, H, Kim, C.H, Kroll, C, Riboldi, M, Newhauser, W, Dedes, G, Fuglsang Jensen, M, Nyström, U.H, Skyt, P.S, Hoffmann, L, Sloth Møller, D, Dokic, I, Kuo, S.H, Tai, P.L, Cheng, S.W, Chong, N.S, Yeom, Y.S, Kuzmin, G, Griffin, K, Langner, U, Jung, J.W, Lee, C, Lee, C.C, Hsu, W, Chao, T.C, Liamsuwan, T, Pischom, N, Tangboonduangjit, P, Suchada, T, Zheng, D, Rutenberg, M, Dhabaan, A, Harrabi, S, MARAFINI, M, Gioscio, E, Yunsheng, D, Alphonse, G, Rodriguez Lafrasse, C, Testa, É, Morris, B, Asavaphatiboon, S, DeBlois, D, Yam, M, Sękowski, P, Skwira-Chalot, I, Matulewicz, T, Flynn, R, Verbeek, N, Smyczek, S, Brualla, L, Lei, Y, Ghavidel, B, Curran, W, Beitler, J, Yu, H.W, Jeng, S.C, Tsai, Y.C, Chiou, J.F, Yusa, K, Dai, T, Yuan, P, Shafai-Erfani, G, Shu, H.K, Pepin, M, Tryggestad, E.J, Abdel Rehim, A, Johnson, J.E, Herman, M.G, Lee, S.C, Sheu, R.J, Ödén, J, Ramos-Mendez, J, Perl, J, Faddegon, B, Alaka, B.G, Bentefour, E.H, Samuel, D, Biradar, B, Frusti, P, Den Otter, L.A, Kurz, C, Stanislawski, M, Landry, G, Meijers, A, Knopf, A.C, Dickmann, J, Wesp, P, Rit, S, Johnson, R.P, Bashkirov, V, Schulte, R.W, Hoyle, B, Johnson, R, Schulte, R, Weller, J, Cotterill, J.V, Waltham, C, Allport, P.P, Taylor, M, Rogers, J, Evans, P.M, Allinson, N.M, Henry, T, Ardenfors, O, Gudowska, I, Poludniowski, G, Dasu, A, Lai, Y, Yuncheng, Z, Yiping, S, Mingwu, J, Xun, J, Yujie, C, Meric, I, Mattingly, J, Moustafa, A, Skjerdal, K, Moteabbed, M, Harisinghani, M, Efstathiou, J.A, Lu, H.M, Kabuki, S, Mizowaki, T, Ofierzynski, R, Paysan, P, Strzelecki, A, Lucca, R, Patch, S, Mustapha, B, Santiago-Gonzalez, D, Pettersen, H.E.S, Sølie, J, Levegrün, S, Pöttgen, C, Meyer, E, Collins-Fekete, C.A, Bashkirov, V.A, Wang, Y.M, Sung, K.C, Wang, C.J, Wu, H.Y, Winter, M, Bauer, U, Hansmann, T, Naumann, J, Peters, A, Pilz, K, Troost, E, Yan, S, Greenhalgh, J, Li, S, Bortfeld, T, Flanz, J, Ytre-Hauge, K, Zhang, L, Sharp, G.C, Cascio, E.W, Flanz, J.B, Tang, J, Zhu, J, Zhang, J, Uh, J, Sarosiek, C, Ricci, J, Coutrakon, G, Ozoemelam, I, van der Graaf, E.R, Maciej, K, Zhang, N, Brandenburg, S, Dendooven, P, Niepel, K, Yohannes, I, Dietrich, O, Ertl-Wagner, B, Pappas, E, Sølie, J.R, Odland, O.H, Ghesquiere-Dierickx, L.M.H, Felix Bautista, R, Gehrke, T, Jakubek, J, Turecek, D, Martisikova, M, Malekzadeh, E, Rajabi, H, Kalantari Mahmoudabadi, F, Meschini, G, d’Arenzo, D, Comini, D, Huynh, M.T, Paganelli, C, Fontana, G, Mancin, A, Preda, L, Su, Z, Henderson, R, Nichols, C, Bryant, C, Mendenhall, W, Boyer, B, Geerebaert, Y, Gevin, O, Koumeir, C, Magniette, F, Manigot, P, Poirier, F, Servagent, N, Thiebaux, C, Verderi, M, Chen, Y.R, Anderle, K, Jeraj, R, Chuter, R, Allan, I, Patel, I, MacKay, R, Harrison, K, Hoole, A, Thomas, S, Jena, R, Liao, Z, Zhu, R.X, Freeman, M, Espy, M, Aulwes, E, Magnelind, P, Merrill, F, Neukirch, L, Sidebottom, R, Tang, Z, Tupa, D, Wilde, C, Shusharina, N, Fullerton, B, Adams, J, Sharp, G, Chan, A, Dolde, K, Naumann, P, Dávid, C, Kachelrieß, M, Saito, N, Pfaffenberger, A, Wolf, M, Lis, M, Moreau, J, Buttion, M, Molitoris, J.K, Simone-, C.B, Regele, H, Bula, C, Danuser, S, Kang, M, Lin, H, Ribeiro, C. O, Dumont, D, Terpstra, J, Knopf, A, Wagenaar, D, Kierkels, R, van der Schaaf, A, Scandurra, D, Sijtsema, M, Korevaar, E, van den Hoek, A, O’Neil, M, Chung, H, Sala, I, Ramirez, H, Guerrero, T, Mondlane, G, Butkus, M.B, Stewart, R.D, Carlson, D.J, Ingram, S, Ytre-Hauge, K. Smeland, Rørvik, E, Perales, A, Carabe, A, Baratto-Roldan, A, Kimstrand, P, Cortes-Giraldo, M, Bertolet, A, Barato-Roldan, A, Baiocco, G, Barbieri, S, Mei, Z, Fan, K, Tang, K, Wang, J, Zhu, H, Sung, W, McNamara, A, Tran, L.T, Qi, Y, Xu, X, Pei, X, Chiang, Y, Chien-Hau, C, Chung-Chi, L, Chuan-Jong, T, Tsi-Chian, C, Wang, L, Cao, J, Wang, X, Lin, E, Minami, K, Kondo, R, Khoei, S, Shirvalilou, S, Khoee, S, Jamali Raoufi, N, Karimi, M.R, Shakeri-Zadeh, A, Patera, V, Rinaldi, I, Sas-Korczynska, B, Deng, W, Karagounis, I, Huynh, K, Maity, A, Abel, E, Santa Cruz, G, Monti Hughes, A, Herrera, M, Trivillin, V, Portu, A, Garabalino, M, Schwint, A, Gonzalez, S, Saint Martin, G, Santa Cruz, I, Tamari, Y, Watanabe, T, Masunaga, S.I, Wittig, A, Nigg, D, Stecher-Rasmussen, F, Moss, R, Igawa, K, Akita, K, Akabori, K, Hattori, K.J, Arima, H, Motoyama, K, Higashi, T, Trivillin, V.A, Pozzi, E.C.C, Thorp1, S.I, Curotto1, P, Garabalino1, M.A, Itoiz, M.E, Santa Cruz, I.S, Ramos, P.S, Palmieri, M.A, Schwint, A.E, Gadan, M.A, Thorp, S.I, Curotto, P, Portu, A.M, Thorp, S, Trivillin, V. A, Schwint, A. E, Fukuo, Y, Kanemitsu, T, Fukumura, M, Kosaka, T, Hiramatsu, R, Kuroiwa, T, Miyatake, S, Kawabata, S, Kirihata, M, Goldfinger, J.A, Garabalino, M.A, Pozzi, E.C, Ramos, P, De Leo, L.N, Yu, Q, Engelbrecht, M, Sioen, S, Miles, X, Nair, S, Ndimba, R, Baeyens, A, Vandevoorde, C, Buizza, G, Meng, J, Takai, N, Ogami, M, Nakamura, S, Ohba, Y, Liu, R.F, Zhang, Q.N, Wang, X.H, Luo, H.T, Kong, Y.R, Jansen, J, Tirinato, L, Marafioti, M.G, Hanley, R, Yao, X.Q, Pagliari, F, Huang, C.Y, Wong, W.K.R, Ho, Y.W, Nam, P.H, Koryakin, S.N, Troshina, M.V, Koryakina, E.V, Potetnya, V.I, Baykuzina, R.M, Lychagin, A.A, Ulyanenko, S.E, Molinelli, S, Giuseppe, M, Tran, L, Bolst, D, James, B, Steinsberger, T, Alliger, C, Dahle, T.J, Rusten, E, Wright, P, Forsback, S, Silvoniemi, A, Minn, H, Andersson, S, Buti, G, Barragán Montero, A.M, Vasquez-Osario, E, Sabouri, P, Nkenge, K, Yi, B, Burigo, L, Greilich, S, Thomas, R, Clark, C, Lourenco, A, Oancea, C, Granja, C, Kodaira, S, Coplan, M, Graybill, J, Lutz, L, Shahi, C, Su, J.J, Thompson, A, Romano, F, Shipley, D, Hong, T.S, Labarbe, R, Wolfgang, J.A, Meyer, S, Bortfeldt, J, Lämmer, P, Schnürle, K, Peters, N, Möhler, C, Hofmann, C, Koschik, A, Bryce-Atkinson, A, Van Nugteren, J, De Rijk, G, Kirby, G, Dutoit, B, Vignati, A, Ahmadi Ganjeh, Z, Fausti, F, Giordanengo, S, Hammad Ali, O, Sacchi, R, Shakarami, Z, Cirio, R, Inoue, J, Tachibana, M, Shimizu, Y, Ochi, T, Amano, D, Miyashita, T, Cooley, J, Nyamane, S, Zwart, T, Wagner, M, Lu, M, Rosenthal, S, Hashimoto, T, Katoh, N, Tamura, H, Emert, F, Missimer, J, Eichenberger, P, Gmuer, C, Spengler, C, Kamp, F, Hofmaier, J, Reiner, M, Belka, C, Van Ooteghem, G, Dasnoy-Sumell, D, Geets, X, Chen, C.C, Galbreath, G, Shmulenson, R, Pinheiro de Almeida, I, van Elmpt, W, Vilches Freixas, G, Unipan, M, Verhaegen, F, Bosmans, G, Garcia, G, Cevallos Robalino, L, Guzman-Garcia, K, Vega-Carrillo, H.R, Gomez-Ros, J.M, Gallego, E, Hintenlang, K, Martin, M, Gupta, N, Meissner, J, Smathers, J, Ainsley, C, Yin, L, Jagt, T, Breedveld, S, van Haveren, R, Nout, R, Astreinidou, E, Staring, M, Heijmen, B, Hoogeman, M, Stokes, W, Matter, M, Nenoff, L, Toramatsu, C, Wakizaka, H, Nitta, M, Nishikido, F, Hirano, Y, Yoshida, E, Miller, J, Maris, A, Kalle, R, Franco, G, Kierkels, R.G.J, van den Hoek, J.G.M, Bijl, H.P, Dieters, M, Steenbakkers, R.J.H.M, Dejongh, F, DeJongh, E, Rykalin, V, Karonis, N, Ordonez, C, Duffin, K, Winans, J, Neph, R, Sanchez-Parcerisa, D, Lopez-Aguirre, M, Dolcet Llerena, A, Udias, J, Oxley, D, Besson, R, Meier, G, Nanz, A, Schorta, M, Fleury, E, Trnková, P, Erdal, E, Hassan, K, Beenakker, J.W, Pignol, J.P, Matysiak, W, Tian, L, Zepter, S, Winterhalter, C, Shim, S, Gouldstone, C, Trnkova, P, Vatnitsky, S, Liu, K, Li, E, Zhuangming, S, Lowenstein, J, De Wilde, O, Bossier, V, Lerot, X, Pouppez, A, Xx, X, Verburg, J, Hueso-Gonzalez, F, Ruggieri, T, Amato, C, Ghesquiere-Dierickx, L, Felix-Bautista, R, Deville, C, Barsky, A, Vapiwala, N, Mohamad, O, Tabuchi, T, Nitta, Y, Nomoto, A, Kasuya, G, Choy, H, Miyashiro, I, Bush, D, Chuong, M, Kozarek, J, Rubens, M, Larson, G, Vargas, C, Hung, S.P, Hsieh, C.E, Huang, B.S, Tsang, N.M, Smith, N, Viehman, J, Harmsen, W, Elswick, S, Boughey, J, Harless, C, Jimenez, R, Hickey, S, DePauw, N, Ho, A, Taghian, A, MacDonald, S, Meek, A, Hedrick, S, Baliga, S, Gallotto, S, Lewy, J, Patteson, B, Speroni, S, Omsberg, A, Tarbell, N, Musolino, P, Yock, T, Indelicato, D, Rotondo, R, Mailhot, R, Uezono, H, Bradfield, S, Agarwal, V, Gillies, C, Gosling, A, Casares-Magaz, O, Eskildsen, S.F, Lassen, Y, Hasle, H, Tofting-Olesen, K, Alapetite, C, Puget, S, Nauraye, C, Beccaria, K, Bolle, S, Doz, F, Sainte-Rose, C, Bouffet, E, Zerah, M, Wu, J, Qiu, X, Hua, W, Mao, Y, Frakulli, R, Kramer, P.H, Glas, M, Blase, C, Tippelt, S, Konrath, L, Gruber, N, Schallerbauer-Peter, A, Mock, U, Niyazi, M, Niemierko, A, Schapira, E, Kim, V, Oh, K.S, Hwang, W.L, Busse, P.M, Loeffler, J.S, Shih, H.A, Appel, H, Tseng, Y.D, Tsai, H, Sinesi, C, Rossi, C, Badiyan, S, Kotecha, R, Pike, L, Horick, N, Yeap, B, Franck, K, Wang, I, Loeffler, J, McKenna, M, Shih, H, Kountouri, M, Kole, A.J, Murray, F.R, Kliebsch, U, Combescure, C, iannalfi, A, Riva, G, Dougherty, J, Kruse, J, Iott, M, Brown, P, Olivier, K, Brodin, P, Kabarriti, R, Schechter, C, Kalnicki, S, Garg, M, Tomé, W, Lu, J.J, Chen, P.J, Dhanireddy, B, Severo, C, Lee, C.H, Lin, C.R, Rosier, L, Mathis, T, DeLaney, T, Lin, S, O’Meara, E, Powell, T, Hong, T, Hall, D, Liu, A, Ntentas, G, Dedeckova, K, Darby, S, Cutter, D, Zapletalova, S, Chen, Y.L, Miao, R, Lee, H, Hsiao-Ming, L, Choy, E, Cote, G, Eulitz, J, Lutz, B, Enghardt, W, Lühr, A, Mcmahon, S, Prise, K, Sung Hyun, L, Tansho, R, Mizushima, K, Warmenhoven, J.W, Hufnagl, A, Friedrich, T, Deycmar, S, Gruber, S, Dörr, W, Pruschy, M, Waissi, W, Burckel, H, Nicol, A, Noel, G, Yousef, I, Koizumi, M, Santa Cruz, G.A, González, S.J, Longhino, J, Provenzano, L, Oña, P, Rao, M, Cantarelli, M.D.L.Á, Leiras, A, Olivera, M.S, Alessandrini, P, Brollo, F, Boggio, E, Costa, H, Ventimiglia, R, Binia, S, Nievas, S.I, Langle, Y, Eijan, A.M, Colombo, L.L, Kawai, K, Nakamura, H, Natsuko, K, Masaki, H, Nakada, M, Furuse, M, Miyatake, S.I, Koivunoro, H, Kankaanranta, L, González, S, Joensuu, H, Sokol, O, Hild, S, Wiedemann, J, Köthe, A, Perry, D, Batie, M, Mascia, A, Sertorio, M, Luhr, A, Suckert, T, Müller, J, Beyreuther, E, Gotz, M, Haase, R, Schürer, M, Tillner, F, von Neubeck, C, Davis, A, Sishc, B, Saha, J, Ding, L, Story, M, Wagner, S, Kim, S.Y, Geary, S, Woodruff, T, Xu, T, Meng, Q, Gilchrist, S, Perentesis, J.P, Zheng, Y, Wells, S.I, Kong, Y, Liu, Y, Geng, Y, Knoll, M, Schwager, C, Schlegel, J, Schnölzer, M, Ding, L.H, Aroumougame, A, Chen, B, Saha, D, Pompos, A, Carter, R, Nickson, C, Thomson, J, Hill, M, Rodrigues, D, Snider, J, Sharma, A, Zakhary, M, Kara, L, Vujaskovic, Z, Dykstra, M, Best, T, Keane, F, Khandekar, M, Fintelmann, F, Willers, H, Singh, P, Eley, J, Malyapa, R, Mahmood, J, Hårdemark, B, Sandison, G.A, Wootton, L.S, Miyoaka, R.S, Laramore, G.E, Yang, P, van der Weide, H, Maduro, J, Heesters, M, Gawryszuk, A, Davila-Fajardo, R, Langendijk, H, Eckhard, M, Maxwell, A, VanNamen, K, Cashin, M, Jacovic, A, Dunn, M, kim, T, Jung, J, Kim, J, Swerdloff, S, Saunders, A, Thomas, J, Kidani, T, Okada, A, Tomida, K, Pennington, H, Xiaoqiang, L, Weigang, H, An, Q, Di, Y, Craig, S, Inga, G, Peyman, K, Xuanfeng, D, Cunningham, C, de Kock, M, Slabbert, J, Panaino, C.M, Phoenix, B, Regan, P.H, Shearman, R, Collins, S.M, Taylor, M.J, Grayson, M, Kato, K, Choi, H, Jang, J.W, Shin, W.G, Min, C.H, McMahon, S, Padilla Cabal, F, Fragoso, J.A, Resch, A.F, Katsis, A, Girdhani, S, Marshall, A, Jackson, I, Bentzen, S, Parry, R, Gantz, S, Schellhammer, S, Hoffmann, A, Delorme, R, Dos Santos, M, Salmon, R, Öden, J, Bullivant, K, Rucksdashal, R, Ferret, E, Covington, F, Rice, S, Decesaris, C, Siddiqui, O, Kowalski, E, Samanta, S, and Rothwell, B
- Subjects
Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0642 ,Physics: Absolute and Relative DosimetryPTC58-0180 ,Biology: Biology and Clinical InterfacePTC58-0685 ,Physics: Commissioning New FacilitiesPTC58-0385 ,Physics: 4D Treatment and DeliveryPTC58-0546 ,Clinics: EyePTC58-0714 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0528 ,Physics: Quality Assurance and VerificationPTC58-0507 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0661 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0221 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0531 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0653 ,Biology: Drug and Immunotherapy CombinationsPTC58-0163 ,Clinics: Sarcoma - LymphomaPTC58-0055 ,Biology: Drug and Immunotherapy CombinationsPTC58-0166 ,Clinics: CNS / Skull BasePTC58-0198 ,Physics: Treatment PlanningPTC58-0421 ,Clinics: PediatricsPTC58-0560 ,General: New HorizonsPTC58-0709 ,Physics: Treatment PlanningPTC58-0664 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0286 ,Physics: Treatment PlanningPTC58-0666 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0346 ,Physics: Treatment PlanningPTC58-0547 ,Physics: Treatment PlanningPTC58-0308 ,Physics: Treatment PlanningPTC58-0549 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0111 ,Physics: Absolute and Relative DosimetryPTC58-0050 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0587 ,Biology: Biology and Clinical InterfacePTC58-0454 ,Physics: Absolute and Relative DosimetryPTC58-0052 ,Physics: Commissioning New FacilitiesPTC58-0395 ,Physics: 4D Treatment and DeliveryPTC58-0534 ,Physics: Dose Calculation and OptimisationPTC58-0072 ,Physics: 4D Treatment and DeliveryPTC58-0533 ,Physics: 4D Treatment and DeliveryPTC58-0538 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0113 ,Physics: Quality Assurance and VerificationPTC58-0633 ,Physics: Treatment PlanningPTC58-0431 ,Physics: Beam Delivery and Nozzle DesignPTC58-0230 ,Biology: Mathematical Modelling SimulationPTC58-0179 ,Clinics: Head and Neck / EyePTC58-0365 ,Physics: Treatment PlanningPTC58-0319 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0697 ,Biology: Biology and Clinical InterfacePTC58-0663 ,Physics: Commissioning New FacilitiesPTC58-0240 ,Physics: Adaptive TherapyPTC58-0177 ,Physics: Commissioning New FacilitiesPTC58-0363 ,Physics: Commissioning New FacilitiesPTC58-0487 ,Physics: 4D Treatment and DeliveryPTC58-0209 ,Physics: 4D Treatment and DeliveryPTC58-0206 ,Clinics: CNS / Skull BasePTC58-0294 ,Physics: Commissioning New FacilitiesPTC58-0127 ,Biology: Mathematical Modelling SimulationPTC58-0068 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0062 ,Physics: 4D Treatment and DeliveryPTC58-0692 ,Physics: Quality Assurance and VerificationPTC58-0723 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0494 ,Physics: Treatment PlanningPTC58-0643 ,Physics: Treatment PlanningPTC58-0521 ,Physics: Treatment PlanningPTC58-0402 ,Physics: Treatment PlanningPTC58-0405 ,Clinics: Head and Neck / EyePTC58-0273 ,Clinics: GIPTC58-0397 ,Physics: Treatment PlanningPTC58-0648 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0489 ,Physics: Quality Assurance and VerificationPTC58-0617 ,Physics: Quality Assurance and VerificationPTC58-0616 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0668 ,Clinics: CNS / Skull BasePTC58-0188 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0625 ,Physics: Treatment PlanningPTC58-0654 ,Physics: Treatment PlanningPTC58-0655 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0133 ,Clinics: PediatricsPTC58-0313 ,Physics: Treatment PlanningPTC58-0659 ,Poster AbstractsClinics: CNSPTC58-0290 ,Physics: Commissioning New FacilitiesPTC58-0064 ,Physics: Adaptive TherapyPTC58-0396 ,Physics: Dose Calculation and OptimisationPTC58-0281 ,Physics: Quality Assurance and VerificationPTC58-0427 ,Physics: Quality Assurance and VerificationPTC58-0669 ,General: New Horizons SessionPTC58-0191 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0217 ,Physics: Quality Assurance and VerificationPTC58-0303 ,Physics: Quality Assurance and VerificationPTC58-0665 ,Clinics: Sarcoma - LymphomaPTC58-0495 ,Physics: Dose Calculation and OptimisationPTC58-0398 ,Physics: Quality Assurance and VerificationPTC58-0667 ,Physics: Quality Assurance and VerificationPTC58-0425 ,Physics: Quality Assurance and VerificationPTC58-0541 ,Physics: Treatment PlanningPTC58-0584 ,Physics: Quality Assurance and VerificationPTC58-0540 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0163 ,Physics: Treatment PlanningPTC58-0224 ,Physics: Treatment PlanningPTC58-0229 ,Clinics: PediatricsPTC58-0249 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0555 ,Clinics: PediatricPTC58-0463 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0556 ,Physics: Absolute and Relative DosimetryPTC58-0498 ,Physics: Commissioning New FacilitiesPTC58-0078 ,Physics: Dose Calculation and OptimisationPTC58-0270 ,Physics: Dose Calculation and OptimisationPTC58-0032 ,Physics: Dose Calculation and OptimisationPTC58-0274 ,Physics: 4D Treatment and DeliveryPTC58-0614 ,Physics: Dose Calculation and OptimisationPTC58-0026 ,Clinics: Head and Neck / EyePTC58-0280 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0091 ,Physics: Treatment PlanningPTC58-0593 ,Biology: Drug and Immunotherapy CombinationsPTC58-0012 ,Physics: Dose Calculation and OptimisationPTC58-0025 ,Physics: Dose Calculation and OptimisationPTC58-0146 ,Clinics: Sarcoma - LymphomaPTC58-0261 ,Physics: Treatment PlanningPTC58-0110 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0733 ,Physics: Quality Assurance and VerificationPTC58-0554 ,Physics: Treatment PlanningPTC58-0597 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0330 ,Physics: Treatment PlanningPTC58-0115 ,Physics: Treatment PlanningPTC58-0598 ,Physics: Absolute and Relative DosimetryPTC58-0040 ,Physics: Absolute and Relative DosimetryPTC58-0282 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0399 ,Physics: Absolute and Relative DosimetryPTC58-0283 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0569 ,Clinics: GUPTC58-0647 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0506 ,Physics: Commissioning New FacilitiesPTC58-0047 ,Physics: Dose Calculation and OptimisationPTC58-0067 ,Clinics: GUPTC58-0409 ,Physics: Dose Calculation and OptimisationPTC58-0065 ,Biology: BNCT Poster Discussion SessionsPTC58-0586 ,Physics: Absolute and Relative Dosimetry PTC58-0393 ,Physics: Image GuidancePTC58-0712 ,Physics: Quality Assurance and VerificationPTC58-0645 ,Physics: Treatment PlanningPTC58-0683 ,Biology: BNCT Poster Discussion SessionsPTC58-0107 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0266 ,Physics: Monitoring and Modelling MotionPTC58-0530 ,Biology: BNCT Poster Discussion SessionsPTC58-0341 ,Physics: Commissioning New FacilitiesPTC58-0172 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0456 ,Physics: Dose Calculation and OptimisationPTC58-0170 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0458 ,Physics: Absolute and Relative DosimetryPTC58-0034 ,Physics: Quality Assurance and VerificationPTC58-0417 ,Physics: Quality Assurance and VerificationPTC58-0413 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0492 ,Physics: Dose Calculation and OptimisationPTC58-0168 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0724 ,Physics: Treatment PlanningPTC58-0694 ,Physics: Adaptive TherapyPTC58-0005 ,Physics: Treatment PlanningPTC58-0696 ,Physics: Treatment PlanningPTC58-0453 ,Physics: Adaptive TherapyPTC58-0366 ,Clinics: BreastPTC58-0197 ,Physics: Beam Delivery and Nozzle DesignPTC58-0652 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0017 ,Physics: Treatment PlanningPTC58-0338 ,Clinics: Head and Neck / EyePTC58-0539 ,General: New Horizons SessionPTC58-0390 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0651 ,General: New HorizonsPTC58-0660 ,Physics: Dose Calculation and OptimisationPTC58-0360 ,Physics: Image GuidancePTC58-0297 ,Physics: 4D Treatment and DeliveryPTC58-0147 ,Scientific: RTTPTC58-0388 ,Physics: Dose Calculation and OptimisationPTC58-0484 ,General: New HorizonsPTC58-0301 ,Physics: Dose Calculation and OptimisationPTC58-0485 ,General: New HorizonsPTC58-0304 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0532 ,Clinics: GIPTC58-0575 ,General: New HorizonsPTC58-0306 ,Physics: Quality Assurance and VerificationPTC58-0589 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0344 ,Physics: Quality Assurance and VerificationPTC58-0225 ,Physics: Treatment PlanningPTC58-0381 ,Physics: Quality Assurance and VerificationPTC58-0467 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0585 ,Physics: Commissioning New FacilitiesPTC58-0416 ,Physics: Quality Assurance and VerificationPTC58-0228 ,Physics: Quality Assurance and VerificationPTC58-0348 ,Physics: Dose Calculation and OptimisationPTC58-0234 ,Physics: Quality Assurance and VerificationPTC58-0101 ,Physics: Treatment PlanningPTC58-0386 ,Physics: Dose Calculation and OptimisationPTC58-0118 ,Physics: Treatment PlanningPTC58-0265 ,Physics: Dose Calculation and OptimisationPTC58-0119 ,Clinics: GIPTC58-0218 ,Physics: Treatment PlanningPTC58-0267 ,Physics: Treatment PlanningPTC58-0387 ,Clinics: BreastPTC58-0142 ,Physics: Treatment PlanningPTC58-0269 ,Physics: Beam Delivery and Nozzle DesignPTC58-0620 ,Clinics: PediatricsPTC58-0048 ,Physics: Quality Assurance and VerificationPTC58-0220 ,Physics: Quality Assurance and VerificationPTC58-0461 ,Physics: Treatment PlanningPTC58-0029 ,Physics: Absolute and Relative DosimetryPTC58-0571 ,Physics: Image GuidancePTC58-0046 ,Clinics: GUPTC58-0557 ,Physics: Absolute and Relative DosimetryPTC58-0211 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0131 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0373 ,General: New HorizonsPTC58-0411 ,Physics: Dose Calculation and OptimisationPTC58-0595 ,Clinics: CNS / Skull BasePTC58-0361 ,General: New HorizonsPTC58-0414 ,General: New HorizonsPTC58-0537 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0628 ,Physics: Treatment PlanningPTC58-0271 ,Physics: Commissioning New FacilitiesPTC58-0307 ,Physics: Quality Assurance and VerificationPTC58-0359 ,Physics: Quality Assurance and VerificationPTC58-0354 ,General: New HorizonsPTC58-0419 ,Physics: Treatment PlanningPTC58-0035 ,Biology: BNCTPTC58-0474 ,Clinics: GIPTC58-0460 ,Biology: BNCTPTC58-0596 ,Clinics: GIPTC58-0222 ,Physics: Image GuidancePTC58-0193 ,Clinics: PediatricPTC58-0312 ,Clinics: GUPTC58-0441 ,Clinics: LungPTC58-0701 ,Clinics: EyePTC58-0536 ,Clinics: GUPTC58-0205 ,Physics: Dose Calculation and OptimisationPTC58-0140 ,Clinics: GUPTC58-0208 ,Physics: Dose Calculation and OptimisationPTC58-0020 ,Physics: Image GuidancePTC58-0195 ,Poster AbstractsClinics: CNSPTC58-0717 ,Physics: Quality Assurance and VerificationPTC58-0325 ,Physics: Dose Calculation and OptimisationPTC58-0015 ,Physics: Commissioning New FacilitiesPTC58-0634 ,General: New HorizonsPTC58-0646 ,Physics: Quality Assurance and VerificationPTC58-0566 ,Physics: Dose Calculation and OptimisationPTC58-0134 ,Physics: Dose Calculation and OptimisationPTC58-0376 ,Biology: Mathematical Modelling SimulationPTC58-0462 ,Biology: BNCTPTC58-0567 ,General: New HorizonsPTC58-0527 ,Physics: Treatment PlanningPTC58-0482 ,Clinics: GI, GU, BreastPTC58-0693 ,Physics: Commissioning New FacilitiesPTC58-0518 ,Physics: Quality Assurance and VerificationPTC58-0686 ,Physics: Quality Assurance and VerificationPTC58-0202 ,Physics: Quality Assurance and VerificationPTC58-0322 ,Physics: Quality Assurance and VerificationPTC58-0564 ,Physics: Quality Assurance and VerificationPTC58-0680 ,Physics: Treatment PlanningPTC58-0247 ,Physics: Quality Assurance and VerificationPTC58-0682 ,Physics: Quality Assurance and VerificationPTC58-0440 ,Biology: Translational and BiomarkersPTC58-0514 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0178 ,Clinics: EyePTC58-0520 ,Physics: Absolute and Relative DosimetryPTC58-0231 ,Clinics: Head and Neck / EyePTC58-0424 ,Physics: Absolute and Relative DosimetryPTC58-0471 ,Physics: Absolute and Relative DosimetryPTC58-0356 ,Physics: Dose Calculation and OptimisationPTC58-0491 ,Physics: Dose Calculation and OptimisationPTC58-0250 ,Physics: Commissioning New FacilitiesPTC58-0650 ,Biology: Biology and Clinical InterfacePTC58-0719 ,Physics: Absolute and Relative DosimetryPTC58-0232 ,Physics: Absolute and Relative DosimetryPTC58-0353 ,General: New HorizonsPTC58-0511 ,Physics: Quality Assurance and VerificationPTC58-0219 ,Physics: Absolute and Relative DosimetryPTC58-0238 ,General: New HorizonsPTC58-0512 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0401 ,Clinics: PediatricPTC58-0688 ,Physics: Quality Assurance and VerificationPTC58-0457 ,Physics: Quality Assurance and VerificationPTC58-0214 ,Physics: Quality Assurance and VerificationPTC58-0459 ,General: New HorizonsPTC58-0516 ,Physics: Treatment PlanningPTC58-0372 ,Physics: Treatment PlanningPTC58-0011 ,Physics: Treatment PlanningPTC58-0254 ,Physics: Quality Assurance and VerificationPTC58-0332 ,Clinics: CNS / Skull BasePTC58-0468 ,Biology: Mathematical Modelling SimulationPTC58-0357 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0649 ,Physics: Dose Calculation and OptimisationPTC58-0006 ,Physics: Quality Assurance and VerificationPTC58-0212 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0565 ,Physics: Treatment PlanningPTC58-0018 ,Physics: Treatment PlanningPTC58-0019 ,Clinics: BreastPTC58-0576 ,Clinics: Head and Neck / EyePTC58-0335 ,Clinics: Head and Neck / EyePTC58-0577 ,General: New HorizonsPTC58-0621 ,Physics: Absolute and Relative DosimetryPTC58-0426 ,Physics: Commissioning New Facilities Poster Discussion SessionsPTC58-0268 ,Physics: Absolute and Relative DosimetryPTC58-0423 ,Physics: Treatment PlanningPTC58-0184 ,Physics: Quality Assurance and VerificationPTC58-0149 ,Clinics: GIPTC58-0378 ,Clinics: GIPTC58-0257 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0662 ,General: New HorizonsPTC58-0627 ,Physics: Treatment PlanningPTC58-0186 ,Physics: Treatment PlanningPTC58-0185 ,Physics: Quality Assurance and VerificationPTC58-0144 ,Biology: BNCT Poster Discussion SessionsPTC58-0602 ,Physics: Treatment PlanningPTC58-0189 ,Physics: Dose Calculation and OptimisationPTC58-0315 ,Clinics: Head and neckPTC58-0300 ,General: New Horizons SessionPTC58-0347 ,Physics: Image GuidancePTC58-0082 ,Clinics: BreastPTC58-0443 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0629 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0007 ,Physics: Commissioning New FacilitiesPTC58-0472 ,Clinics: GI, GU, BreastPTC58-0515 ,Physics: Dose Calculation and Optimisation Poster Discussion SessionsPTC58-0606 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0450 ,Physics: Absolute and Relative DosimetryPTC58-0657 ,Physics: Dose Calculation and OptimisationPTC58-0551 ,Physics: Treatment PlanningPTC58-0192 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0675 ,Physics: Treatment PlanningPTC58-0194 ,Physics: Dose Calculation and OptimisationPTC58-0544 ,Physics: Treatment PlanningPTC58-0199 ,Physics: Quality Assurance and VerificationPTC58-0037 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0207 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0434 ,Physics: Quality Assurance and VerificationPTC58-0036 ,Physics: Quality Assurance and VerificationPTC58-0278 ,Physics: Quality Assurance and VerificationPTC58-0394 ,Physics: Quality Assurance and VerificationPTC58-0151 ,Physics: Quality Assurance and VerificationPTC58-0154 ,Physics: Dose Calculation and OptimisationPTC58-0428 ,Clinics: BreastPTC58-0116 ,Biology: Enhanced Biology in Treatment Planning Poster Discussion SessionsPTC58-0435 ,Physics: Commissioning New FacilitiesPTC58-0681 ,Physics: Absolute and Relative DosimetryPTC58-0323 ,Physics: Dose Calculation and OptimisationPTC58-0583 ,Physics: Absolute and Relative DosimetryPTC58-0448 ,Clinics: CNS / Skull BasePTC58-0251 ,General: New HorizonsPTC58-0721 ,Physics: Absolute and Relative DosimetryPTC58-0203 ,Physics: Dose Calculation and OptimisationPTC58-0455 ,Physics: 4D Treatment and DeliveryPTC58-0130 ,Physics: Commissioning New FacilitiesPTC58-0679 ,Physics: Absolute and Relative DosimetryPTC58-0329 ,General: New HorizonsPTC58-0604 ,Physics: Absolute and Relative DosimetryPTC58-0449 ,Clinics: CNS / Skull BasePTC58-0132 ,General: New HorizonsPTC58-0607 ,Physics: Quality Assurance and VerificationPTC58-0122 ,Physics: Quality Assurance and VerificationPTC58-0243 ,Physics: Treatment PlanningPTC58-0165 ,Oral AbstractsPhysics: Dose Calculation and OptimisationPTC58-0437 ,Physics: 4D Treatment and DeliveryPTC58-0377 ,Physics: Quality Assurance and VerificationPTC58-0125 ,Physics: Quality Assurance and VerificationPTC58-0245 ,Physics: Dose Calculation and OptimisationPTC58-0337 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0334 ,Physics: Quality Assurance and VerificationPTC58-0121 ,General: New Horizons SessionPTC58-0563 ,General: New Horizons SessionPTC58-0321 ,Clinics: Head and Neck / EyePTC58-0477 ,Physics: Quality Assurance and VerificationPTC58-0480 ,Clinics: GUPTC58-0010 ,Clinics: EyePTC58-0684 ,Clinics: GUPTC58-0496 ,Clinics: Head and neckPTC58-0676 ,Clinics: GUPTC58-0137 ,Physics: Beam Delivery and Nozzle Design Poster Discussion SessionsPTC58-0256 ,Physics: 4D Treatment and DeliveryPTC58-0117 ,Physics: Absolute and Relative DosimetryPTC58-0552 ,Physics: Absolute and Relative DosimetryPTC58-0310 ,Physics: Absolute and Relative DosimetryPTC58-0672 ,Physics: Absolute and Relative DosimetryPTC58-0436 ,Physics: Dose Calculation and OptimisationPTC58-0452 ,Physics: Dose Calculation and OptimisationPTC58-0331 ,Physics: Commissioning New FacilitiesPTC58-0213 ,Biology: Mathematical Modelling SimulationPTC58-0272 ,Clinics: EyePTC58-0326 ,Physics: Commissioning New FacilitiesPTC58-0568 ,Physics: Dose Calculation and OptimisationPTC58-0444 ,Physics: Quality Assurance and VerificationPTC58-0379 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0095 ,Physics: Treatment PlanningPTC58-0053 ,Physics: Absolute and Relative DosimetryPTC58-0438 ,Physics: Absolute and Relative DosimetryPTC58-0317 ,Physics: Quality Assurance and VerificationPTC58-0497 ,Physics: Quality Assurance and VerificationPTC58-0375 ,Physics: Treatment PlanningPTC58-0056 ,Physics: 4D Treatment and DeliveryPTC58-0124 ,Clinics: GIPTC58-0009 ,Physics: Quality Assurance and VerificationPTC58-0014 ,Physics: Quality Assurance and VerificationPTC58-0374 ,Clinics: LungPTC58-0727 ,General: New Horizons SessionPTC58-0578 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0470 ,Clinics: LungPTC58-0204 ,Clinics: Head and neckPTC58-0227 ,Clinics: LungPTC58-0446 ,Physics: Quality Assurance and VerificationPTC58-0190 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0609 ,Clinics: LungPTC58-0689 ,General: New HorizonsPTC58-0021 ,General: New HorizonsPTC58-0262 ,Biology: BNCT Poster Discussion SessionsPTC58-0081 ,Clinics: GIPTC58-0726 ,General: New HorizonsPTC58-0145 ,Physics: Image GuidancePTC58-0573 ,General: New HorizonsPTC58-0027 ,General: New HorizonsPTC58-0028 ,Biology: Mathematical Modelling and SimulationPTC58-0148 ,Physics: Dose Calculation and OptimisationPTC58-0635 ,Physics: Image GuidancePTC58-0215 ,Physics: Image GuidancePTC58-0336 ,Poster AbstractsClinics: CNSPTC58-0535 ,Physics: Quality Assurance and VerificationPTC58-0187 ,Biology: BNCT Poster Discussion SessionsPTC58-0084 ,General: New Investigator SessionPTC58-0339 ,General: New Horizons SessionPTC58-0420 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0523 ,Biology: BNCT Poster Discussion SessionsPTC58-0088 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0112 ,Physics: Quality Assurance and VerificationPTC58-0182 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0615 ,Physics: Quality Assurance and VerificationPTC58-0080 ,Biology: BNCTPTC58-0085 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0722 ,General: New HorizonsPTC58-0253 ,General: New HorizonsPTC58-0255 ,Clinics: PediatricPTC58-0703 ,General: New HorizonsPTC58-0499 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0380 ,General: New HorizonsPTC58-0259 ,Clinics: GI, GU, BreastPTC58-0288 ,Clinics: GI, GU, BreastPTC58-0045 ,Physics: Absolute and Relative DosimetryPTC58-0619 ,Clinics: PediatricPTC58-0707 ,Physics: Quality Assurance and VerificationPTC58-0196 ,Physics: Quality Assurance and VerificationPTC58-0074 ,Physics: Quality Assurance and VerificationPTC58-0077 ,Biology: BNCT Poster Discussion SessionsPTC58-0073 ,Biology: BNCTPTC58-0075 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0093 ,Clinics: GUPTC58-0161 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0371 ,Physics: Monitoring and Modelling MotionPTC58-0181 ,General: New HorizonsPTC58-0120 ,General: New HorizonsPTC58-0362 ,General: New HorizonsPTC58-0364 ,Physics: Image GuidancePTC58-0473 ,Scientific: RTTPTC58-0641 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0296 ,General: New HorizonsPTC58-0004 ,General: New HorizonsPTC58-0128 ,Clinics: BreastPTC58-0316 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0236 ,General: New HorizonsPTC58-0008 ,General: New Investigator SessionPTC58-0673 ,Physics: Quality Assurance and VerificationPTC58-0167 ,Physics: Quality Assurance and VerificationPTC58-0289 ,Physics: Quality Assurance and VerificationPTC58-0284 ,General: New Horizons SessionPTC58-0522 ,Physics: Quality Assurance and VerificationPTC58-0164 ,Physics: Quality Assurance and VerificationPTC58-0285 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0623 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0502 ,Clinics: GUPTC58-0293 ,Biology: Translational and BiomarkersPTC58-0599 ,Biology: BNCTPTC58-0063 ,Clinics: LungPTC58-0656 ,General: New HorizonsPTC58-0592 ,Biology: BNCT Poster Discussion SessionsPTC58-0092 ,Poster AbstractsClinics: CNSPTC58-0302 ,Physics: Image GuidancePTC58-0464 ,General: New HorizonsPTC58-0352 ,Physics: Image GuidancePTC58-0465 ,General: New HorizonsPTC58-0476 ,Physics: Image GuidancePTC58-0100 ,General: New HorizonsPTC58-0235 ,Biology: Mathematical Modelling and SimulationPTC58-0349 ,Physics: Treatment PlanningPTC58-0094 ,Physics: 4D Treatment and Delivery Poster Discussion SessionsPTC58-0367 ,Physics: Dose Calculation and OptimisationPTC58-0400 ,Biology: Translational and BiomarkersPTC58-0244 ,Physics: Dose Calculation and OptimisationPTC58-0640 ,Biology: Mathematical Modelling and SimulationPTC58-0355 ,General: New Investigator SessionPTC58-0320 ,Physics: Quality Assurance and VerificationPTC58-0057 ,Physics: Quality Assurance and VerificationPTC58-0174 ,Physics: Quality Assurance and VerificationPTC58-0295 ,Physics: Dose Calculation and OptimisationPTC58-0529 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0123 ,Physics: Quality Assurance and VerificationPTC58-0171 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0049 ,Clinics: BreastPTC58-0731 ,General: New HorizonsPTC58-0223 ,General: New HorizonsPTC58-0102 ,General: New HorizonsPTC58-0466 ,Scientific: RTTPTC58-0503 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0389 ,General: New HorizonsPTC58-0108 ,General: New HorizonsPTC58-0109 ,Physics: Commissioning New FacilitiesPTC58-0736 ,Biology: Mathematical Modelling and SimulationPTC58-0343 ,Biology: Mathematical Modelling and SimulationPTC58-0342 ,Clinics: GI, GU, BreastPTC58-0237 ,Physics: Dose Calculation and OptimisationPTC58-0711 ,Biology: Mathematical Modelling and SimulationPTC58-0581 ,Clinics: GI, GU, BreastPTC58-0114 ,Clinics: Base of SkullPTC58-0730 ,Clinics: Head and neckPTC58-0383 ,Clinics: CNS / Skull BasePTC58-0559 ,Clinics: Base of SkullPTC58-0613 ,General: New HorizonsPTC58-0691 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0054 ,General: New HorizonsPTC58-0210 ,Clinics: BreastPTC58-0729 ,General: New HorizonsPTC58-0574 ,Clinics: GI, GU, BreastPTC58-0239 ,Scientific: RTTPTC58-0637 ,General: New HorizonsPTC58-0579 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0176 ,General: New HorizonsPTC58-0699 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0156 ,Biology: Mathematical Modelling and SimulationPTC58-0333 ,Biology: Translational and BiomarkersPTC58-0345 ,Physics: Image GuidancePTC58-0369 ,Physics: Commissioning New FacilitiesPTC58-0509 ,Biology: Mathematical Modelling SimulationPTC58-0658 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0051 ,General: New Investigator SessionPTC58-0548 ,Clinics: GI, GU, BreastPTC58-0241 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0412 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0024 ,Clinics: LungPTC58-0226 ,Biology: Biological Differences between Carbon, Proton and Photons Poster Discussion SessionsPTC58-0069 ,General: New HorizonsPTC58-0562 ,General: New HorizonsPTC58-0561 ,General: New HorizonsPTC58-0201 ,Biology: Mathematical Modelling and SimulationPTC58-0439 ,General: New HorizonsPTC58-0445 ,General: New HorizonsPTC58-0324 ,Physics: Image GuidancePTC58-0031 ,Biology: Mathematical Modelling and SimulationPTC58-0558 ,Physics: Image GuidancePTC58-0392 ,Biology: Mathematical Modelling and SimulationPTC58-0678 ,Physics: Beam Delivery and Nozzle DesignPTC58-0090 ,General: New Investigator SessionPTC58-0630 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0524 ,Physics: Commissioning New FacilitiesPTC58-0713 ,Clinics: GI, GU, BreastPTC58-0139 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0248 ,Clinics: CNS / Pediatrics / Lung Poster Discussion SessionsPTC58-0368 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0519 ,General: New Horizons SessionPTC58-0720 ,Physics: Quality Assurance and VerificationPTC58-0083 ,General: New HorizonsPTC58-0311 ,General: New HorizonsPTC58-0674 ,General: New HorizonsPTC58-0553 ,Physics: Image GuidancePTC58-0023 ,Scientific: RTTPTC58-0612 ,General: New HorizonsPTC58-0677 ,Biology: Mathematical Modelling and SimulationPTC58-0545 ,Physics: Dose Calculation and OptimisationPTC58-0601 ,Physics: Dose Calculation and OptimisationPTC58-0725 ,Physics: Quality Assurance and VerificationPTC58-0098 ,Physics: Dose Calculation and OptimisationPTC58-0605 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0517 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0618 ,Physics: Monitoring and Modelling MotionPTC58-0481 ,Clinics: GI / Sarcoma Poster Discussion SessionsPTC58-0071 ,Physics: Adaptive TherapyPTC58-0351 ,Physics: 4D Treatment and DeliveryPTC58-0702 ,Physics: Image GuidancePTC58-0734 ,Physics: Image GuidancePTC58-0611 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0486 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0442 ,Biology: Drug and Immunotherapy CombinationsPTC58-0327 ,Clinics: Head and Neck / EyePTC58-0096 ,Clinics: LungPTC58-0159 ,Physics: Treatment PlanningPTC58-0708 ,General: New HorizonsPTC58-0097 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0350 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0016 ,Physics: Adaptive TherapyPTC58-0104 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0433 ,Physics: Image GuidancePTC58-0608 ,Biology: Translational and Biomarkers Poster Discussion SessionsPTC58-0610 ,Clinics: Head and neckPTC58-0058 ,Physics: Treatment PlanningPTC58-0715 ,Clinics: Head and neckPTC58-0298 ,Clinics: EyePTC58-0099 ,General: New HorizonsPTC58-0086 ,General: New HorizonsPTC58-0089 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0200 ,Poster AbstractsClinics: CNSPTC58-0157 ,Clinics: LungPTC58-0141 ,Clinics: LungPTC58-0260 ,Clinics: LungPTC58-0264 ,Physics: Image GuidancePTC58-0513 ,Physics: Image GuidancePTC58-0631 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0469 ,Biology: BNCT Poster Discussion SessionsPTC58-0384 ,Physics: Image GuidancePTC58-0639 ,Clinics: PediatricsPTC58-0700 ,Clinics: LungPTC58-0136 ,Clinics: BreastPTC58-0706 ,General: New HorizonsPTC58-0079 ,Biology: Drug and Immunotherapy Combinations Poster Discussion SessionsPTC58-0406 ,Clinics: Base of SkullPTC58-0382 ,Physics: Image GuidancePTC58-0624 ,Physics: Beam Delivery and Nozzle DesignPTC58-0173 ,Biology: Drug and Immunotherapy CombinationsPTC58-0358 ,Poster AbstractsClinics: CNSPTC58-0690 ,General: New HorizonsPTC58-0061 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0580 ,Physics: Monitoring and Modelling MotionPTC58-0162 ,Physics: Adaptive TherapyPTC58-0550 ,Physics: Adaptive TherapyPTC58-0430 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0103 ,General: New Investigator SessionPTC58-0252 ,Physics: Quality Assurance and VerificationPTC58-0704 ,Physics: Image GuidancePTC58-0418 ,Clinics: Base of SkullPTC58-0572 ,Clinics: Lung / Sarcoma / LymphomaPTC58-0106 ,Physics: Beam Delivery and Nozzle DesignPTC58-0022 ,Physics: Monitoring and Modelling MotionPTC58-0279 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0447 ,Physics: Treatment PlanningPTC58-0622 ,Clinics: PediatricsPTC58-0644 ,Biology: Biology and Clinical InterfacePTC58-0490 ,Clinics: CNS / Skull BasePTC58-0716 ,General: New HorizonsPTC58-0292 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0570 ,General: New HorizonsPTC58-0059 ,Physics: Quality Assurance and VerificationPTC58-0710 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0216 ,Physics: Image GuidancePTC58-0404 ,Physics: Image GuidancePTC58-0525 ,Physics: Image GuidancePTC58-0526 ,Poster AbstractsClinics: CNSPTC58-0328 ,Clinics: LungPTC58-0070 ,Clinics: Eye / Breast / Pelvis Poster Discussion SessionsPTC58-0135 ,Biology: BNCT Poster Discussion SessionsPTC58-0391 ,Physics: Treatment PlanningPTC58-0510 ,Physics: Treatment PlanningPTC58-0636 ,Physics: Treatment PlanningPTC58-0638 ,Physics: Image GuidancePTC58-0408 ,Physics: Absolute and Relative Dosimetry Poster Discussion SessionsPTC58-0632 ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0318 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0246 ,Clinics: PediatricsPTC58-0504 ,General: New HorizonsPTC58-0160 ,Physics: Image Guidance Poster Discussion SessionsPTC58-0076 ,Physics: Monitoring and Modelling MotionPTC58-0143 ,Biology: Mathematical Modelling and SimulationPTC58-0718 ,Physics: Image GuidancePTC58-0671 ,Clinics: LungPTC58-0183 ,Physics: Image GuidancePTC58-0670 ,Report ,Physics: Treatment Planning Poster Discussion SessionsPTC58-0422 ,Biology: Biological Differences between Carbon / Proton and Photons Carbons / Proton and PhotonPTC58-0129 ,Physics: Adaptive Therapy Poster Discussion SessionsPTC58-0705 ,Biology: Enhanced Biology in Treatment PlanningPTC58-0258 ,General: New HorizonsPTC58-0030 ,General: New HorizonsPTC58-0150 ,Biology: Biology and Clinical InterfacePTC58-0479 ,General: New HorizonsPTC58-0153 ,Clinics: PediatricPTC58-0087 ,General: New HorizonsPTC58-0152 ,General: New HorizonsPTC58-0155 ,General: New HorizonsPTC58-0033 ,General: New HorizonsPTC58-0158 ,Physics: Image GuidancePTC58-0429 ,Biology: Translational and BiomarkersPTC58-0287 ,Physics: Adaptive TherapyPTC58-0403 ,Physics: Image GuidancePTC58-0309 - Published
- 2020
3. FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
- Author
-
Markova, J., Kobe, C., Skopalova, M., Klaskova, K., Dedeckova, K., Plütschow, A., Eich, H.T., Dietlein, M., Engert, A., and Kozak, T.
- Published
- 2009
- Full Text
- View/download PDF
4. An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?
- Author
-
Ntentas, G., primary, Dedeckova, K., additional, Andrilik, M., additional, Shakir, R., additional, Aznar, M.C., additional, Ramroth, J., additional, Begum, R., additional, Darby, S., additional, Mikhaeel, G., additional, and Cutter, D., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
- Author
-
Ntentas, G, Dedeckova, K, Andrlik, M, Aznar, M, George, B, Kubeš, J, Darby, S, and Cutter, D
- Subjects
Adult ,Male ,Organs at Risk ,Manchester Cancer Research Centre ,Adolescent ,ResearchInstitutes_Networks_Beacons/mcrc ,Radiotherapy Planning, Computer-Assisted ,Radiotherapy Dosage ,Middle Aged ,Hodgkin Disease ,Article ,Treatment Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Proton Therapy ,Humans ,Female ,Radiotherapy, Intensity-Modulated ,Radiotherapy, Conformal ,Radiation Injuries - Abstract
Purpose Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics. Methods and materials Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified. Results Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT. Conclusions PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT.
- Published
- 2019
6. EP-1268: Breast cancer irradiation using proton pencil beam scanning
- Author
-
Pasztorova, A., primary, Kubes, J., additional, Andrlik, M., additional, Ondrova, B., additional, Kasacova, G., additional, Dedeckova, K., additional, Slavikova, S., additional, Vitek, P., additional, Vinakurau, S., additional, Kvech, J., additional, Vondracek, V., additional, and Navratil, M., additional
- Published
- 2018
- Full Text
- View/download PDF
7. Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated With Advanced Proton Beam Therapy Compared to Photon Radiation Therapy
- Author
-
Ntentas, G., primary, Dedeckova, K., additional, Andrilik, M., additional, Aznar, M.C., additional, George, B., additional, Darby, S.C., additional, and Cutter, D., additional
- Published
- 2017
- Full Text
- View/download PDF
8. PREDICTED CARDIAC AND SECOND CANCER RISKS IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ADVANCED PROTON BEAM THERAPY COMPARED TO PHOTON RADIOTHERAPY
- Author
-
Ntentas, G., primary, Dedeckova, K., additional, Andrilik, M., additional, Aznar, M.C., additional, George, B., additional, Darby, S., additional, and Cutter, D., additional
- Published
- 2017
- Full Text
- View/download PDF
9. How and why to monitor Pseudomonas aeruginosa infections in the long term at a cystic fibrosis centre.
- Author
-
Kalferstova, L., Dedeckova, K. Vilimovska, Antuskova, M., Melter, O., Drevinek, P., and Vilimovska Dedeckova, K
- Abstract
Background: Pseudomonas aeruginosa is a major cystic fibrosis (CF) pathogen causing chronic respiratory infections and posing a risk for cross-infection between patients with CF.Aim: To propose an algorithm for long-term surveillance of P. aeruginosa and assess its suitability for monitoring the epidemiological situation at a CF centre with approximately 300 patients.Methods: Over a nine-year period, over 300 P. aeruginosa isolates from 131 infected patients were tested by multi-locus sequence typing (MLST) and/or random amplified polymorphic DNA (RAPD) assay.Findings: MLST analysis led to the identification of 97 different sequence types which were distributed among 17 RAPD-generated (pseudo)clusters. This indicates that the easy-to-perform RAPD assay is only suitable for intra-individual, not interindividual, strain analyses. No epidemic strains were observed. Longitudinal analysis revealed that 110 of the 131 patients were infected with the same strain over the observation period, whereas 21 patients had a strain replacement or a new infection. Chronic infection was found in 99 of the 131 patients, and the remaining 32 patients met the criteria for intermittent infection (as defined by the Leeds criteria). Eighteen of the 32 patients (56%) with intermittent infection were infected with the same strain for up to nine years.Conclusion: The strain type only changed in 16% of 131 patients with chronic or intermittent infection. As many as 56% of patients considered to have intermittent infection were actually chronically infected with the same strain for many years. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
10. Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome
- Author
-
Jiri Kubes, Dedeckova, K., Cvek, J., Vondracek, V., Dvorak, J., Argalacsova, S., Navratil, M., and Buril, J.
- Subjects
Adult ,Aged, 80 and over ,Male ,Antineoplastic Agents, Hormonal ,Prostatic Neoplasms ,Radiotherapy Dosage ,Chemoradiotherapy ,Adenocarcinoma ,Middle Aged ,Prognosis ,Neoadjuvant Therapy ,Survival Rate ,Humans ,Prospective Studies ,Neoplasm Grading ,Radiotherapy, Conformal ,Aged ,Follow-Up Studies ,Neoplasm Staging - Abstract
The aim of this work was to prospectively analyze the outcome of combined hormonal treatment and radical radiotherapy in high risk non metastatic prostate cancer patients (T1=4, N0-1, M0).Between April 2003 and December 2007 196 patients with high risk prostate cancer were treated with curative intent. The treatment consisted of 2-month neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional 2-year adjuvant hormonal treatment.The median follow up time was 59 months. Fiveyear overall survival was 86% and 5-year biochemical disease free survival (DFS) 70%. Factors found to be statistically significant relative to outcomes were Gleason score (p=0.017), initial PSA value (p=0.039) and adjuvant hormonal treatment (p=0.035). There was no significant association between radiotherapy dose or volume and biochemical DFS (bDFS). Late genitourinary and gastrointestinal toxicity was acceptable.Treatment combining hormonal therapy and radical radiotherapy can be recommended for this subgroup of prostate cancer patients. Adjuvant hormonal treatment should also be used.
- Published
- 2013
11. 124 Ribosomal RNA intergenic spacer analysis (RISA) as a rapid and diagnostic means to profile microbial diversity in cystic fibrosis sputum
- Author
-
Flight, W.G., primary, Marchesi, J.R., additional, Norville, P., additional, Dedeckova, K., additional, Bull, M., additional, Bright-Thomas, R.J., additional, Mutton, K.J., additional, Dřevínek, P., additional, Jones, A.M., additional, and Mahenthiralingam, E., additional
- Published
- 2013
- Full Text
- View/download PDF
12. 131 Surveillance of Pseudomonas aeruginosa infections at the Prague CF centre
- Author
-
Kalferstova, L., primary, Dedeckova, K., additional, Antuskova, M., additional, Nemec, A., additional, and Dřevínek, P., additional
- Published
- 2013
- Full Text
- View/download PDF
13. WS5.1 A high degree of variation in virulence of clonal Burkholderia cenocepacia ST32 isolates from cystic fibrosis patients in zebra fish embryos
- Author
-
Dedeckova, K., primary, Vergunst, A., additional, and Dřevínek, P., additional
- Published
- 2013
- Full Text
- View/download PDF
14. 113 A novel diagnostic PCR for identification of highly transmissible Burkholderia cenocepacia ST32 infection
- Author
-
Dedeckova, K., primary, Kalferstova, L., additional, Vavrova, J., additional, and Drevinek, P., additional
- Published
- 2012
- Full Text
- View/download PDF
15. 7127 POSTER Radical Radiotherapy of Bladder Cancer 64-74 Gy
- Author
-
Zapletal, R., primary, Kubes, J., additional, Dedeckova, K., additional, and Soukup, V., additional
- Published
- 2011
- Full Text
- View/download PDF
16. 137* The end of a long-term outbreak with highly transmissible Burkholderia cenocepacia ST32
- Author
-
Dedeckova, K., primary, Fila, L., additional, Skalicka, V, additional, Bartosova, J., additional, Vavrova, V., additional, Zemkova, D., additional, Kucerova, T., additional, Cinek, O., additional, and Drevinek, P., additional
- Published
- 2011
- Full Text
- View/download PDF
17. The role of PCR in early diagnosis and monitoring of infection with Burkholderia cepacia complex
- Author
-
Dedeckova, K., primary, Cinek, O., additional, Melter, O., additional, and Drevinek, P., additional
- Published
- 2010
- Full Text
- View/download PDF
18. Radical Radiotherapy of Bladder Cancer 64-74 Gy
- Author
-
Zapletal, R., Jiri Kubes, Dedeckova, K., and Soukup, V.
19. Proton Therapy in Supradiaphragmatic Lymphoma: Predicting Treatment-Related Mortality to Help Optimize Patient Selection.
- Author
-
Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, Begum R, Kubeš J, Darby SC, Mikhaeel NG, and Cutter DJ
- Subjects
- Humans, Patient Selection, Radiotherapy Dosage, Smoking, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy, Proton Therapy adverse effects, Proton Therapy methods
- Abstract
Purpose: In some patients with Hodgkin lymphoma (HL), proton beam therapy (PBT) may reduce the risk of radiation-related cardiovascular disease (CVD) and second cancers (SC) compared with photon radiation therapy (RT). Our aim was to identify patients who benefit the most from PBT in terms of predicted 30-year absolute mortality risks (AMR
30 ) from CVD and SC, taking into account individual background, chemotherapy, radiation, and smoking-related risks., Methods and Materials: Eighty patients with supradiaphragmatic HL treated with PBT between 2015 and 2019 were replanned using optimal photon RT. To identify patients predicted to derive the greatest benefit from PBT compared with photon RT, doses and AMR30 from CVD and SC of the lung, breast, and esophagus were compared for all patients and across patient subgroups., Results: For patients with mediastinal disease below the origin of the left main coronary artery (n = 66; 82%), PBT reduced the mean dose to the heart, left ventricle, and heart valves by 1.0, 2.7, and 3.6 Gy, respectively. Based on U.S. mortality rates, PBT reduced CVD AMR30 by 0.2%, from 5.9% to 5.7%. The benefit was larger if the mediastinal disease overlapped longitudinally with the heart by ≥40% (n = 23; 29%). PBT reduced the mean dose to the heart, left ventricle, and heart valves by 3.2, 5.6, and 5.1 Gy, respectively, and reduced CVD AMR30 by 0.8%, from 7.0% to 6.2%. For patients with axillary disease (n = 25; 31%), PBT reduced the mean lung dose by 2.8 Gy and lung cancer AMR30 by 0.6%, from 2.7% to 2.1%. Breast and esophageal doses were also lower with PBT, but the effects on AMR30 were negligible. The effect of smoking on CVD and lung cancer AMR30 was much larger than radiation and chemotherapy and the differences between radiation modalities., Conclusions: The predicted benefit of PBT is not universal and limited to certain categories of patients with lymphoma and lower mediastinal or axillary disease. Smoking cessation should be strongly encouraged in smokers who require thoracic RT., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
20. Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration.
- Author
-
Tseng YD, Hoppe BS, Dedeckova K, Patel CG, Hill-Kayser CE, Miller DM, Maity A, Mendenhall NP, Mailhot Vega RB, Yock TI, Baliga S, Hess CB, Winkfield KM, Mohindra P, Rosen LR, Tsai H, Chang J, Hartsell WF, and Plastaras JP
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Recurrence, Risk Factors, Treatment Outcome, Young Adult, Lymphoma radiotherapy, Mediastinum, Proton Therapy adverse effects, Radiation Pneumonitis etiology
- Abstract
Purpose: Despite high response rates, there has been reluctance to use radiation therapy for patients with relapsed/refractory (r/r) Hodgkin (HL) or aggressive non-Hodgkin lymphoma (NHL) given concerns for subacute and late toxicities. Symptomatic pneumonitis, a subacute toxicity, has an incidence of 17% to 24% (≥grade 2) even with intensity modulated radiation therapy. Proton therapy (PT), which has no exit radiation dose, is associated with a lower dose to lung compared with other radiation techniques. As risk of radiation pneumonitis is associated with lung dose, we evaluated whether pneumonitis rates are lower with PT., Methods and Materials: Within an international, multi-institutional cohort, we retrospectively evaluated the incidence and grade of radiation pneumonitis (National Cancer Institute Common Terminology Criteria for Adverse Events v4) among patients with r/r HL or NHL treated with PT., Results: A total of 85 patients with r/r lymphoma (66% HL, 34% NHL; 46% primary chemorefractory) received thoracic PT from 2009 to 2017 in the consolidation (45%) or salvage (54%) setting. Median dose was 36 Gy(RBE). Before PT, patients underwent a median of 1 salvage systemic therapy (range, 0-4); 40% received PT within 4 months of transplant. With a median follow-up of 26.3 months among living patients, 11 patients developed symptomatic (grade 2) pneumonitis (12.8%). No grade 3 or higher pneumonitis was observed. Dose to lung, including mean lung dose, lung V5, and V20, significantly predicted risk of symptomatic pneumonitis, but not receipt of brentuximab, history of bleomycin toxicity, sex, or peritransplant radiation., Conclusions: PT for relapsed/refractory lymphoma was associated with favorable rates of pneumonitis compared with historical controls. We confirm that among patients treated with PT, pneumonitis risk is associated with mean lung and lung V20 dose. These findings highlight how advancements in radiation delivery may improve the therapeutic ratio for patients with relapsed/refractory lymphoma. PT may be considered as a treatment modality for patients with relapsed/refractory lymphoma in the consolidation or salvage setting., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
- Author
-
Ntentas G, Dedeckova K, Andrlik M, Aznar MC, George B, Kubeš J, Darby SC, and Cutter DJ
- Subjects
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Hodgkin Disease drug therapy, Humans, Male, Middle Aged, Organs at Risk, Proton Therapy adverse effects, Radiation Injuries etiology, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted methods, Radiotherapy, Conformal methods, Radiotherapy, Intensity-Modulated methods, Treatment Outcome, Hodgkin Disease radiotherapy, Proton Therapy methods
- Abstract
Purpose: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics., Methods and Materials: Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified., Results: Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT., Conclusions: PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
22. Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.
- Author
-
Tseng YD, Cutter DJ, Plastaras JP, Parikh RR, Cahlon O, Chuong MD, Dedeckova K, Khan MK, Lin SY, McGee LA, Shen EY, Terezakis SA, Badiyan SN, Kirova YM, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, and Hoppe BS
- Subjects
- Breast Neoplasms etiology, Diabetes Mellitus etiology, Female, Gastrointestinal Neoplasms etiology, Humans, Hypothyroidism etiology, Lung Neoplasms etiology, Male, Neoplasms, Radiation-Induced etiology, Neoplasms, Second Primary etiology, Organs at Risk radiation effects, Radiotherapy Dosage, Hodgkin Disease radiotherapy, Lymphoma, Non-Hodgkin radiotherapy, Proton Therapy adverse effects
- Published
- 2017
- Full Text
- View/download PDF
23. Novel diagnostic PCR assay for Burkholderia cenocepacia epidemic strain ST32 and its utility in monitoring infection in cystic fibrosis patients.
- Author
-
Dedeckova K, Kalferstova L, Strnad H, Vavrova J, and Drevinek P
- Subjects
- Burkholderia Infections epidemiology, Humans, Population Surveillance, Burkholderia Infections complications, Burkholderia Infections diagnosis, Burkholderia cenocepacia classification, Cystic Fibrosis complications, Polymerase Chain Reaction methods
- Abstract
Background: A highly transmissible Burkholderia cenocepacia sequence type (ST) 32 strain caused a major outbreak at the Prague Cystic Fibrosis (CF) Centre in the late 1990s and early 2000s. Because a large number of CF patients were affected by ST32, a rapid and easy-to-use diagnostic tool for ST32 infection was urgently needed for the detection of new cases as well as for long-term surveillance. The present study sought to identify unique DNA sequences within the ST32 genome to develop an ST32 strain-specific PCR assay., Methods: Genomic subtractive hybridisation between B. cenocepacia ST32 and the closely related genome-sequenced strain B. cenocepacia ST28 identified a 325 bp long region that was absent in all but one Burkholderia strain, as demonstrated by our newly designed PCR., Results: Out of 57 strains, only B. cenocepacia ST33 cross-reacted with ST32, resulting in a PCR specificity of 98.2%. This specificity was further tested by various genotyping methods, which revealed the practical indistinguishibility of ST32 and ST33. The PCR sensitivity, checked on a panel of 50 ST32 clinical isolates, was 100%. A closer examination of the ST32-specific sequence revealed no significant homology apart from a fragment of the ISBmu3 transposase., Conclusions: This novel ST32-specific PCR assay allows the rapid and reliable detection of a globally distributed B. cenocepacia epidemic strain. Its routine use is especially well suited to infection surveillance programs for CF populations with a high rate of ST32 infection. This PCR method can also be used to detect ST33, a clonal variant of ST32., (Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
24. Treatment of high risk prostate cancer with combined radiotherapy and hormonal treatment- results and identification of factors influencing outcome.
- Author
-
Kubes J, Dedeckova K, Cvek J, Vondrácek V, Dvorak J, Argalacsová S, Navrátil M, and Buril J
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Follow-Up Studies, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Staging, Prognosis, Prospective Studies, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Radiotherapy Dosage, Radiotherapy, Conformal, Survival Rate, Adenocarcinoma mortality, Antineoplastic Agents, Hormonal therapeutic use, Chemoradiotherapy, Prostatic Neoplasms mortality
- Abstract
Purpose: The aim of this work was to prospectively analyze the outcome of combined hormonal treatment and radical radiotherapy in high risk non metastatic prostate cancer patients (T1=4, N0-1, M0)., Methods: Between April 2003 and December 2007 196 patients with high risk prostate cancer were treated with curative intent. The treatment consisted of 2-month neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68-78 Gy, conformal technique) and an optional 2-year adjuvant hormonal treatment., Results: The median follow up time was 59 months. Fiveyear overall survival was 86% and 5-year biochemical disease free survival (DFS) 70%. Factors found to be statistically significant relative to outcomes were Gleason score (p=0.017), initial PSA value (p=0.039) and adjuvant hormonal treatment (p=0.035). There was no significant association between radiotherapy dose or volume and biochemical DFS (bDFS). Late genitourinary and gastrointestinal toxicity was acceptable., Conclusion: Treatment combining hormonal therapy and radical radiotherapy can be recommended for this subgroup of prostate cancer patients. Adjuvant hormonal treatment should also be used.
- Published
- 2013
25. PCR detection of Burkholderia cepacia complex as one of key factors to handle a long-term outbreak.
- Author
-
Dedeckova K, Fila L, Skalicka V, Bartosova J, Kucerova T, Vavrova V, Zemkova D, Kalferstova L, Melter O, Cinek O, and Drevinek P
- Subjects
- Adult, Bacterial Typing Techniques, Czech Republic epidemiology, Disease Outbreaks prevention & control, Disease Outbreaks statistics & numerical data, Female, Humans, Infection Control methods, Male, Respiratory Tract Infections epidemiology, Respiratory Tract Infections microbiology, Respiratory Tract Infections prevention & control, Sputum microbiology, Burkholderia Infections diagnosis, Burkholderia Infections epidemiology, Burkholderia Infections prevention & control, Burkholderia cepacia complex genetics, Burkholderia cepacia complex isolation & purification, Cystic Fibrosis epidemiology, Cystic Fibrosis microbiology, Polymerase Chain Reaction methods, Polymerase Chain Reaction statistics & numerical data
- Abstract
Background: Once the outbreak with Burkholderia cenocepacia ST32 was identified in the Prague cystic fibrosis (CF) centre, molecular tools were implemented into diagnostic routine in order to complement infection control measures with as accurate as possible microbiological service. In addition, genotyping techniques were applied as part of an infection surveillance program to assign species and strain status in samples positive for Burkholderia cepacia complex (Bcc). We sought to evaluate a usefulness of Bcc-specific PCR in infection control and to map evolution of the outbreak., Methods: Since 2001, 6109 respiratory samples from 299 CF patients were examined not only by conventional culture, but also by PCR, detecting Bcc directly in sputum., Results: Diagnosis of Bcc infection was established by culture in 54 patients already prior to 2001. As 39 more patients were diagnosed by culture and/or PCR during 2001-2010, this represented annual prevalence of 18.5%-28.9%. Twelve of 39 patients were culture negative at the time of their first PCR positivity. Although 2/3 of them became subsequently culture positive, the time delay in diagnostics of the infection by culture ranged from 1 to 22 months. New cases of Bcc infection were detected every year, however a dramatic drop was observed for the epidemic strain ST32., Conclusion: A likely factor contributing to the end of ST32 epidemic was segregation of Bcc infected patients that included also patients with no culture, but PCR positivity. The diagnostic PCR led to timely identification of cases with 'culture-invisible' infection., (Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
26. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
- Author
-
Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, Dedeckova K, Eich HT, Böll B, Dietlein M, and Kozak T
- Subjects
- Adolescent, Adult, Bleomycin administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Drug Administration Schedule, Etoposide administration & dosage, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Hodgkin Disease diagnosis, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prednisone administration & dosage, Procarbazine administration & dosage, Prognosis, Radiopharmaceuticals, Time Factors, Treatment Outcome, Vincristine administration & dosage, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hodgkin Disease diagnostic imaging, Hodgkin Disease drug therapy, Positron-Emission Tomography methods
- Abstract
The prognostic value of positron emission tomography (PET) in early therapy response assessment, after completion of chemotherapy and 3 months after the end of treatment in advanced Hodgkin lymphoma (HL) remains to be defined. We report the results of 69 patients with first presentation of advanced HL. [18F]-fluoro-2-deoxy-d-glucose (FDG)-PET scan was performed after four cycles (PET-4), on completion of chemotherapy after 6/8 cycles (PET-6/8) and 3 months after the completion of chemotherapy (PET 3-months). Median follow-up was 55 months. The negative predictive value (NPV) for PET-4, PET-6/8 and PET 3-months was 98%, 95% and 97%, respectively. The 4-year progression-free survival (PFS) for PET-4 negative (n = 51) and PET-4 positive (n = 18) patients was 96% and 78%, respectively (p = 0.016). The 4-year PFS for PET-6/8 negative (n = 59) and PET-6/8 positive (n = 9) patients was 95% and 78%, respectively (p = 0.046). Patients with a large mediastinal mass constituted nearly all of the PET-4 positive (16/18) and PET-6/8 positive (8/9) patients. After radiotherapy of PET-6/8 positive patients, PET 3-months was negative in 64 (97%) and positive in two (3%) patients. PET 3-months after the end of chemotherapy was of limited value when the interim PET-4 was negative. Interim PET after four cycles of bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone (BEACOPP) is a strong prognostic marker for PFS in advanced HL.
- Published
- 2012
- Full Text
- View/download PDF
27. Direct culture-independent Strain typing of Burkholderia cepacia complex in sputum samples from patients with cystic fibrosis.
- Author
-
Drevinek P, Vosahlikova S, Dedeckova K, Cinek O, and Mahenthiralingam E
- Subjects
- Burkholderia cepacia complex genetics, Cluster Analysis, DNA, Bacterial chemistry, DNA, Bacterial genetics, Genotype, Humans, Sequence Analysis, DNA, Bacterial Typing Techniques methods, Burkholderia Infections microbiology, Burkholderia cepacia complex classification, Cystic Fibrosis complications, Pneumonia, Bacterial microbiology, Sputum microbiology
- Abstract
We examined if multilocus sequence typing (MLST), a method for genotyping and species identification of Burkholderia cepacia complex bacteria, could be applied directly to cystic fibrosis sputum. The redesigned nested-PCR MLST format was successfully used to accurately identify strains in 23 sputum samples, of which 8 were culture negative.
- Published
- 2010
- Full Text
- View/download PDF
28. Prognostic impact of bone involvement in Hodgkin lymphoma.
- Author
-
Feltl D, Markova J, Mocikova H, Dedeckova K, and Kozak T
- Subjects
- Adult, Bone Neoplasms drug therapy, Bone Neoplasms pathology, Female, Hodgkin Disease drug therapy, Hodgkin Disease pathology, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prognosis, Bone Neoplasms mortality, Hodgkin Disease mortality
- Abstract
The purpose of the study is to determine incidence and prognostic impact of osseous Hodgkin lymphoma (HL). Between 1997 and 2004, 198 patients with HL were treated at our institution. Advanced stages and nodular sclerosis histology prevailed. All patients were treated according to protocols of the German Hodgkin Study Group (GHSG). After minimum follow-up of 24 months, we retrospectively analyzed the incidence of osseous HL, treatment response and parameters of survival. We recorded 14 cases of osseous HL (7 %), always with concurrent nodal disease. Axial skeleton was most frequently involved. Eleven patients (78,5 %) achieved complete remission and three (21,5 %) progressed primarily. The patients with osseous HL had significantly lower 2-year freedom from treatment failure than the patients without bone involvement (71,4 and 92,7 %, respectively, p=0,004), with no significant difference in 2-year overall survival (85,7 and 95 %, respectively, p=0,14). On multivariate analysis, advanced stage was the only independent adverse prognostic factor. In conclusion, bone involvement is a relatively common finding in HL and is not an independent adverse prognostic factor.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.